














Cardiovascular Disease Risk Behaviors in 
Human Immunodeficiency Virus-Positive Populations: 


















Submitted in partial fulfillment of the 
requirements for the degree of 
Doctor of Philosophy 
under the Executive Committee 




















































All rights reserved 
  
ABSTRACT 
Cardiovascular Disease Risk Behaviors in 
Human Immunodeficiency Virus-Positive Populations: 




Cardiovascular disease (CVD) risk behaviors, namely tobacco smoking, hazardous alcohol use, 
poor diet and sedentary behavior, are more prevalent among people living with HIV (PLWH) 
than the general population. Qualitative evidence shows that PLWH report adopting unhealthy 
behaviors as a means of coping with the stress of living with HIV, including the adverse 
physiological symptoms of HIV infection, the psychological stress of being aware of one’s HIV 
status, and the physiological and psychological impacts of being on HIV treatment. These 
observations suggest that being HIV-positive may have a causal influence on CVD risk 
behaviors and that these causal effects likely differ across stages of the HIV continuum. To date, 
few quantitative studies have been conducted to examine these causal relationships. The goal of 
this dissertation was to explore the effects of HIV continuum stage on CVD risk behaviors and 
assess several plausible stress-coping mechanisms, as motivated by established stress-coping 
theory. This dissertation consisted of three studies. First, a systematic review was conducted to 
examine the existing quantitative evidence for the causal effects of HIV continuum stage on 
CVD risk behaviors. Findings from this review revealed that being HIV-positive is associated 
with excess smoking and drinking, and that while receipt of a positive HIV diagnosis is 
associated with short-term improvements in some CVD risk behaviors, these improvements are 
unlikely to be maintained long-term. Overall, however, the existing studies suffer important 
methodological limitations, notably inadequate characterization of HIV continuum stage. The 
second study was an empirical analysis of patterns of self-reported CVD risk behaviors across 
the HIV continuum among a population-based sample of 4,061 adults aged 40 years and over 
living in rural Agincourt district in South Africa. Results showed no consistent evidence of an 
association between HIV continuum stage and hazardous alcohol use or sedentary behavior. 
However, higher prevalence of smoking was observed specifically among males who were HIV-
positive and aware of their status but not on treatment, compared to those who were HIV-
negative. There was no evidence of mediation by various measures of physiological and/or 
psychological stress. The third study was an analysis of whether perceived life expectancy (PLE) 
modifies the effects of HIV continuum stage on CVD risk behaviors. Observed associations were 
most prominent among individuals with low PLE and null among those with high PLE. Overall, 
this dissertation contributed to greater understanding of the relationship between CVD risk 
behaviors among HIV-infected persons across the HIV continuum. Findings did not support a 
stress-coping hypothesis; however, PLE was found to be a potentially useful indicator of 
individuals who are most likely to smoke in the presence of HIV. This dissertation also fills 
evidence gaps among older adults in sub-Saharan Africa, an under-studied population with high 
and increasing burdens of both HIV and CVD. As HIV-positive population survive longer on 
antiretroviral therapy and the prevention of age-related conditions becomes increasingly 
important, these findings may help inform future research and the development of CVD 
prevention interventions. 
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1.1.1. Cardiovascular disease risk behaviors in HIV 
In the era of antiretroviral therapy (ART), the survival of people living with HIV (PLWH) on 
treatment has approached that of the general population.1 However, age-related chronic 
conditions such as cardiovascular disease (CVD) have become increasingly important 
contributors to their morbidity and mortality.2-5 As a result, CVD prevention has become a top 
health priority for HIV-positive individuals. Current CVD prevention efforts aim to achieve 
routine screening and management of modifiable CVD risk factors,6 centered around managing 
clinical risk factors (e.g., hypertension, dyslipidemia and diabetes) via direct pharmacological 
therapies and adjustment of HIV treatment regimens to reduce exposure to known cardiovascular 
ART toxicities.7-10 However, there is growing recognition of the importance of behavioral risk 
factors for CVD. HIV treatment guidelines recommend “advising all HIV-positive persons to 
maintain a healthy lifestyle” by reducing tobacco smoking, hazardous alcohol use, and avoiding 
unhealthy diet and exercise habits.6 Furthermore, modifying unhealthy lifestyle behaviors may 
be relatively inexpensive and provide benefits for overall health and well-being, making them 
favorable CVD prevention targets.11-13 
CVD risk behaviors are highly prevalent among PLWH. The prevalence of smoking in HIV-
positive populations is estimated to be between 30-60%, up to 2-3 times that of the general 
population.14-20 The prevalence of hazardous alcohol use is between 1.5 to 2 times as high.21-25 
Diet and exercise behaviors have received less research attention, but some studies have shown, 
for example, higher levels of excessive dietary fat intake26 and insufficient exercise27, 28 in HIV-
 2 
positive persons as compared to uninfected controls. These findings often persist after 
controlling for known demographic and socioeconomic confounders and have been replicated 
across diverse populations, including those in both high and low resource settings. 
1.1.2. Does HIV itself influence CVD risk behaviors? 
The reasons for these differences have not been well-established, though alcohol use and 
smoking are typically considered to be antecedents of HIV acquisition, as they often co-occur in 
social situations that are conducive to risky sexual behavior.29 As a result, alcohol use and 
smoking are most often examined as risk factors of HIV acquisition, as well as barriers to HIV 
testing, retention in HIV care and adherence to ART.30-33 Less research attention has been placed 
on the opposite causal relationship—to examine whether HIV itself influences unhealthy 
lifestyle behaviors—despite the existence of plausible mechanisms through which this could 
occur. 
HIV exhibits a wide array of adverse physiological and psychological manifestations. 
Physiological manifestations include symptoms of HIV infection, such as fatigue,34 pain due to 
HIV-related neuropathy (a consequence of infection and common side effect of HIV 
medications),35 and muscle weakness, as well as outcomes associated with advanced HIV disease 
progression, such as physical dysfunction as measured by difficulties with activities of daily 
living (ADLs),36-38 and even cognitive difficulties such as impaired memory and concentration.39 
In addition, a number of psychological manifestations of HIV exist, including elevated levels of 
depression and anxiety,40, 41 and diminished subjective well-being as measured by self-reported 
quality of life and life satisfaction.42, 43 
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Taken together, these phenomena illustrate the diverse types of stress to which PLWH are 
exposed. Links between stress and CVD risk behavior engagement are well-established in the 
general population, and evidence suggests that HIV-related stress similarly contributes to health 
outcomes in HIV-positive populations.44-46 However, prior studies have focused predominantly 
on clinical outcomes such as HIV disease progression and virologic or immunological function, 
rather than health behaviors.47 In qualitative studies, PLWH are known to often report feeling 
overwhelmed by their diagnosis,48 and adopting smoking or drinking behaviors to obtain relief 
from the physical symptoms of HIV, such as nausea and pain.48-51 or distraction from the 
psychological stress of living with HIV.52-55 Unhealthy dietary and sedentary lifestyles have not 
been studied extensively among PLWH, but stress-related eating and sedentary behaviors have 
been observed in other disease contexts, e.g., among breast cancer patients who experience 
discomforts from chemotherapy treatment and maintain fears of cancer recurrence.56 In other 
words, HIV itself may have a causal influence on CVD risk behaviors via a stress-coping 
mechanism; yet, few existing studies have quantitatively tested this hypothesis.34, 57-59 
 Stress-coping theory 
Historically, the term stress has been conceptualized in various ways, including concepts as 
disparate as traumatic or impactful life events, subjective emotions, psychological symptoms 
(e.g., depression), and even biological markers (e.g., measured cortisol levels or autonomic 
nervous system activity). To clarify terminology, a brief note on stress-coping theory is needed. 
Stress-coping theories have an extensive history in multiple fields including medicine and 
psychology, in which the label stress carries different meanings.60 Here, stressor is defined as 
any event or condition that imposes some physical or psychological demands on a person. Stress 
is defined as the individual’s subjective experience of confronting these demands—that is, stress 
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is the psychological response to a perceived stressor. Lazarus’ stress appraisal theory states than 
an individual who encounters a potential stressor undergoes the cognitive process of appraisal, 
where he/she evaluates whether the potential stressor constitutes a meaningful threat or harm and 
whether he/she has the resources to overcome it.61 To illustrate, incurring an injury may cause 
anxiety in some individuals but may not in others, e.g., those who feel capable of achieving full 
recovery. The injury therefore may cause some but not all individuals to “feel stressed”. Those 
who do may cope via different types of coping responses: cognitive (e.g., solution-seeking or 
avoidant thinking) and/or behavioral (e.g., removing the source of stress or engaging in 
distracting behaviors). 
This theoretical framework can be applied to the current research question. Each of the 
physiological manifestations of HIV can be conceptualized as a potential source of stress 
(physiological stressor). To the extent that individuals engage in unhealthy CVD risk behaviors 
to cope with these stressors, they would act as mediators of a causal effect of HIV on CVD risk 
behaviors, explaining why HIV-positive individuals engage in higher rates of CVD risk 
behaviors than uninfected individuals. Some psychological phenomena, such as depressive 
symptoms, low self-reported quality of life and low life satisfaction, may serve as proxies for an 
individual’s psychological experience of stress.62 If so, these measures would also act as 
potential mediators of a causal effect of HIV on CVD risk behaviors.44, 46, 63-65 
Further insights may be gleaned from a related stress-coping theory, Leventhal’s self-regulation 
model of illness. Self-regulation theory states that individuals regulate their responses to health 
stressors, such as HIV, in accordance with their internal cognitive representation of it.66, 67 
Among other things, this illness representation involves evaluating its anticipated consequences, 
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the timeline of those consequences, and the perceived control one has to change future 
outcomes.68 These concepts underscore the importance of one’s ability to make accurate 
predictions about the future as determinants of health prevention behaviors.69-72 Within this 
theoretical framework, an individual’s perceived life expectancy (PLE) may regulate how PLWH 
engage in CVD risk behaviors as a stress-coping response to their illness. Simply, PLE may be 
an effect modifier of the relationship between HIV and CVD risk behaviors. 
 Dissertation overview 
As HIV-infected populations survive and age in the era of ART, preventing CVD and other age-
related comorbidities will be increasingly important.73 Unhealthy lifestyle behaviors, which are 
prevalent and modifiable, represent potentially high-yield targets for intervention. Further 
research on the relationship between HIV and CVD risk behavior engagement, motivated by 
established stress-coping theories, may enhance understanding of the etiology of and inform 
prevention of CVD risk in this population. 
This dissertation is organized into five chapters. Following this introductory chapter, three 
chapters are devoted to the three analytical aims of the dissertation: (aim 1) to systematically 
review the available evidence of the causal effects of HIV on CVD risk behaviors; (aim 2) to 
explore the patterns of CVD risk behavior engagement across stages of the HIV continuum and 
whether these relationships are explained by hypothesized mediators, as predicted by stress-
coping theory; and (aim 3) to assess whether PLE modifies the relationships between HIV 
continuum stage and CVD risk behaviors. The final chapter synthesizes the findings of this 
dissertation and discusses implications for public health and directions for future research.  
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 DOES HIV CAUSE CARDIOVASCULAR DISEASE RISK BEHAVIORS? 
A SYSTEMATIC REVIEW OF EVIDENCE ACROSS THE HIV CONTINUUM 
 Abstract 
Background: Studies have demonstrated that cardiovascular disease (CVD) risk behaviors 
(smoking, hazardous alcohol use, poor dietary habits and sedentary behaviors) are more 
prevalent among people living with HIV (PLWH) as compared to the general population. While 
the reasons for these differences are not well-established, qualitative studies suggest that PLWH 
often turn to unhealthy behaviors to cope with the stress of living with their illness, including the 
adverse physiological symptoms of HIV infection, the psychological stress of being aware of 
one’s HIV status, and the physiological and psychological impacts of being on HIV treatment. 
These observations suggest that being HIV-positive may have a causal influence on CVD risk 
behaviors and that these causal effects likely differ across stages of the HIV continuum. 
However, few quantitative studies to date have been conducted specifically to test whether being 
HIV-positive causes increased CVD risk behaviors. In this study, we systematically reviewed the 
available literature in support of causal effects of HIV continuum stage on CVD risk behaviors. 
Methods: Pubmed, Web of Science, EMBASE and PsycINFO databases were searched to 
identify all peer-reviewed articles published between 2000-2018 that compared CVD risk 
behaviors by HIV continuum stage, defined as either HIV infection status, awareness, treatment 
or immune/virologic recovery. Articles were eligible for inclusion if they assessed relationships 
between HIV continuum stage (four groups: HIV-negative, HIV-positive but unaware of HIV 
status, HIV-positive and aware of HIV status but not on treatment, and HIV-positive on 
treatment) and any CVD risk behavior. We reviewed studies for methodological quality, 
observed findings, and variability for each HIV continuum stage and across demographic groups. 
 14 
Results: We included 81 articles in this review, representing 30 analyses on smoking, 54 on 
alcohol use, 2 on dietary behaviors and 6 on sedentary behaviors; nineteen (19%) of these were 
longitudinal. We found that smoking and alcohol use were the ones most commonly studied 
(33% and 58% of available analyses, respectively). Studies used widely disparate measures and 
sampling methods, and observed findings were widely inconsistent across studies. Generally, 
results support positive associations between HIV infection and awareness status and increased 
smoking and alcohol use, and protective associations between HIV treatment and immune/viral 
recovery and decreased smoking and alcohol use. Findings for dietary and sedentary behaviors 
were less clear due to insufficient sample size. 
Discussion: This review showed that most studies were cross-sectional and that there was wide 
variability in methods used across studies. The paucity of longitudinal studies reflects 
methodological difficulties and the historical tendency to conceptualize CVD risk behaviors, 
particularly smoking and alcohol, as predictors, rather than consequences, of HIV acquisition, 
awareness of HIV infection after testing and treatment. Future research is required to examine 
the effects of HIV continuum stage on CVD risk behaviors directly in order to strengthen causal 
claims and to assess underlying mechanisms.  
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 Introduction 
People living with HIV (PLWH) experience excess cardiovascular disease (CVD)-related 
morbidity and mortality compared to the general population, due to, among other things, higher 
rates of several CVD risk behaviors, including tobacco smoking, hazardous alcohol use, poor 
diet and sedentary behaviors.1 Smoking prevalence is estimated to be between 30-60%, up to 2-3 
times that of the general population,2-9 and hazardous alcohol use is between 1.5 to 2 times as 
high.10-14 Poor diet and sedentary behaviors in this population are less well-understood, but some 
studies have shown, for example, higher levels of dietary fat intake15 and insufficient exercise16, 
17 among HIV-positive persons than uninfected controls. These findings often persist after 
controlling for known demographic and socioeconomic confounders and have been replicated 
across diverse settings. 
The reasons for these differences have not been fully established, in part because CVD risk 
behaviors may be both antecedents and consequences of HIV. Most existing research among 
PLWH has focused on smoking and alcohol use, treating them as risk factors of HIV acquisition, 
as well as common barriers to HIV testing, HIV care attendance, and antiretroviral treatment 
(ART) adherence.18-21 Smoking and alcohol use are known to occur in social situations that are 
conducive to risky sexual behavior.22 However, growing qualitative evidence also shows that 
PLWH often report seeking unhealthy behaviors as a means of coping with their illness,23, 24 a 
behavioral stress-coping response that occurs even among those who recognize the harms and 
express the desire to change.25-27 
Quantitative evidence for the causal influence of HIV infection on CVD risk behaviors is 
currently lacking, partly reflecting a historical tendency for researchers to focus efforts on HIV 
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prevention. More importantly, the quantitative evidence that does exist is inconsistent. This is 
likely a result of some key methodological difficulties. First, lifestyle behaviors are difficult to 
measure, as they are most readily assessed by self-report and can be prone to social desirability 
bias. Second, temporality is not easily established as they are, by definition, highly time-variant 
and few studies examine long-term CVD risk behavior patterns as an outcome of interest among 
HIV-positive populations. Given the high costs required to sufficiently follow individuals 
prospectively and observe their long-term behaviors, cross-sectional studies are naturally the 
most commonly employed study designs on this topic. Third, most studies are conducted in 
clinic-based or convenience samples, which is a known source of selection bias.28 Fourth, despite 
the fact that plausible stress-coping mechanisms have been identified in the qualitative literature, 
few investigators explicitly articulate the underlying mechanisms when conducting quantitative 
studies. This results in ambiguity regarding how variables are selected and measured, what role 
they are hypothesized to play, and ultimately how to interpret results. Specifically, if a stress-
coping hypothesis is true, individuals who use unhealthy behaviors to “cope with HIV” may be 
responding to the physical symptoms of HIV,29-31 the psychological toll of receiving a positive 
HIV diagnosis,32-34 or the physical and/or psychological consequences of being on HIV 
treatment.17 HIV, as an exposure, is measured inconsistently across studies; some studies 
compare individuals without HIV infection to those with HIV infection, regardless of whether 
they are aware of their status, while other studies compare self-reported HIV-positives with self-
reported negatives, without distinguishing actual HIV infection status, and some studies compare 
treated versus untreated individuals. Observed findings would be expected to vary depending on 
the measure used i.e., across different stages of the HIV continuum. Furthermore, it is possible 
that individuals within each of these stages of the HIV continuum may have different effects 
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across people or time. Being aware of one’s HIV status, for example, may be a positive health 
motivator for some individuals but may instead be a source of anxiety for others, or may simply 
have decreasing influence as time passes. The complex motivations for health behaviors among 
PLWH are firmly supported within established theories of health behavior and remain an area of 
active research.35, 36  
Due to these gaps, there is no clear consensus regarding the effects of HIV on CVD risk 
behaviors. Nonetheless, HIV care and treatment guidelines recommend that clinicians routinely 
advise all HIV-positive persons to maintain healthy behaviors as a key component of CVD 
prevention.37 Better understanding of the unique motivations for unhealthy behaviors, and in 
particular the influence of HIV-positive status itself, is crucial to these efforts. 
In this study, we systematically reviewed the available quantitative evidence, with particular 
attention to differences across HIV continuum stages and over time. We also examined the 
quality of evidence with respect to measurement and sampling, as well as variability in findings 
across demographic groups and settings. 
 Methods 
PubMed, Web of Science, EMBASE and PsycINFO databases were searched for all studies that 
examined the relationship between HIV continuum stage and any of the four CVD risk behaviors 
(full search term details are reported in Appendix Table 5.1). We also scanned the reference lists 
of selected articles for additional relevant articles missed in the initial search. For this analysis, 
smoking and alcohol use included any current or recent measures of smoking tobacco products 
or alcoholic beverages, respectively, exclusive of illicit drug use. Due to the absence of standard 
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definitions of dietary or sedentary behaviors, all measures were considered eligible for inclusion. 
Studies must have been conducted among adults (age 15 and older) and published in English 
since 2000 (i.e., after combination ART became widely available). Non-empirical papers 
(reviews and commentaries), qualitative studies, and studies designed to test CVD risk behavior 
modification intervention (e.g., counseling, peer support, education, and/or pharmacologic 
therapies that target the behavior of interest) were excluded. 
We prioritized longitudinal studies with measures of behavior change within the same individual 
over time. These consisted primarily of two types. Analyses with measures of self-reported 
behavior change before versus after a change in HIV continuum stage were classified as pre/post 
behavior change analyses (e.g., proportion of prior smokers who quit after receiving their HIV 
diagnosis). In contrast, we classified analyses with repeated measures of the behavior over time 
as trajectory analyses (e.g., smoking prevalence over time among HIV-positive vs. HIV-negative 
groups at baseline). The key difference is the time at which HIV continuum stage was measured 
relative to when the CVD risk behavior was measure. After an initial review returned relatively 
few longitudinal studies with repeated measures of a CVD risk behavior over time, we expanded 
the search to include cross-sectional analyses (i.e., those that compared behavior prevalence at 
one time between groups of individuals at different HIV continuum stages), regardless of the 
direction of causation hypothesized by the authors.a Exceptions were made to exclude studies 
                                                 
a Some analyses were conducted within longitudinal cohorts but utilized only cross-sectional 
data , e.g., from the baseline or most recent study visit. These were considered cross-sectional 
analyses for this review. 
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where the CVD risk behavior was known to occur prior to HIV acquisition(e.g., alcohol use as a 
risk factor for unprotected sex among HIV-positive versus HIV-negative groups). 
After identifying potentially eligible studies, relevant information was downloaded into EndNote 
and reviewed by author, year and title to remove duplicates. Titles were initially screened to 
identify studies eligible for inclusion; then two independent reviewers, AP and DHb, screened 
abstracts to confirm eligibility and discussed discrepancies to obtain consensus. Finally, the full 
text of each article was reviewed to confirm eligibility, and extract and summarize study 
characteristics. Extracted data included author(s), publication year, geographic region, sample 
size, sampling method, variable measurement (i.e., self-report or biomarker, time frame, etc.), 
covariates adjusted in the analysis (if any), and observed findings. We synthesized results and 
described the availability and quality of evidence for each CVD risk behavior by HIV continuum 
stage. 
 Results 
Figure 2.1 displays the systematic review flowchart. The initial search yielded a total of 3,835 
titles. After removing duplicates, we screened titles of 2,939 articles and deemed 2,692 as 
irrelevant. The abstracts of the remaining 247 articles were reviewed, after which 104 were 
retained for full text review. Twenty-three were further excluded based on full-text review for 
the following reasons: no comparison made across HIV continuum stage (n=15), no available 
full text article (n=3), no appropriate measure of CVD risk behavior (n=3), study tested a CVD 
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risk behavior modification intervention (n=1), and study conducted prior to 2000 (n=1). Several 
articles investigated multiple CVD risk behaviors and were treated as multiple analyses for the 
purpose of this review. Ultimately, we included in the review 81 published articles, representing 
a total of 94 unique analyses: 30 on smoking,5, 7, 8, 36, 38-63 54 on alcohol use,7, 10, 11, 35, 39, 51, 57, 58, 60, 
64-108 two on dietary behaviors,47, 109 and six on sedentary behaviors47, 52, 57, 64, 110, 111. Eighteen 
(19%) of these were longitudinal: seven on smoking,36, 38, 40, 47, 53, 59, 62 nine on alcohol use,35, 66, 67, 
74, 81, 83, 88, 91, 108 two on dietary behaviors,47, 109 and one on sedentary behaviors47. 
Extracted data from all longitudinal analyses are reported separately by CVD risk behavior in 
Tables 2.1-2.4 (data for all cross-sectional analyses are in Appendix Tables 5.2-5.5). Alcohol use 
and smoking were the most frequently studied of the four outcomes (58% and 33% of 
longitudinal analyses, respectively). Overall, the majority of longitudinal analyses were 
conducted in hospital- or clinic-based settings (13/18, 72%), with a few exceptions conducted in 
population-based (n=2, 11%)35, 36 or community-based/respondent-driven samples (n=3, 17%)59, 
64, 81. The distribution of sampling methods was similar among the cross-sectional analyses 
(Table 2.5). 
2.3.1. Smoking 
Of the seven available longitudinal analyses on smoking (Table 2.1), three assessed changes in 
smoking pre/post HIV diagnosis. Among those who smoked previously, the estimates of 
prevalence of self-reported cessation post HIV diagnosis ranged between 19% to 49%.36, 47, 59 
Three analyses used group-based trajectory modeling on repeated smoking measures data to 
assess differences in smoking trajectories by baseline HIV status; these analyses found no 
significant effect of HIV-positive status on subsequent smoking trajectories (median follow-up 
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ranged 4-9 years, with assessments every 6 or 12 months).38, 53, 59 Generally, findings from 
trajectory analyses showed little variability in long-term smoking patterns; in a study of 6,577 
men who have sex with men (MSM) in the established Multicenter AIDS Cohort Study (MACS), 
90% of participants were characterized as having no change in their smoking status throughout 
the entire follow-up period.38 Two analyses assessed smoking changes pre/post HIV care 
initiation; findings suggested that care initiation was associated with modest short-term 
improvements in smoking.40, 62 Of note, one study found that while intention to quit smoking 
increased three months after initiating care, these trends diminished from 3 to 12 months. 
Intention to quit was also associated with advanced HIV disease, as measured by CD4+ cell 
count and viral load (VL), but actual achievement of smoking cessation (i.e., confirmed by 
expired CO) was not.62 
Twenty-three cross-sectional analyses on smoking were reviewed (Appendix Table 5.2). These 
studies were conducted in a wide variety of demographic groups; however, most (15/23, 65%) 
were conducted in high-resource settings, such as the US, Canada, Europe or Australia.5, 7, 39, 41-44, 
46, 48, 49, 52, 56, 57, 60, 61, 63 Three analyses (13%) used biomarker measures (e.g., blood cotinine or 
expired CO).44, 50, 62 Overall, the results from these cross-sectional analyses showed that being 
HIV-infected was generally associated with higher smoking prevalence. Similarly, being aware 
of one’s HIV-positive status was generally associated with higher smoking prevalence. However, 
some studies comparing self-reported HIV-positives to self-reported HIV-negatives included 
only truly HIV-infected individuals while others included HIV-uninfected individuals as well; 
thus, results cannot be easily compared even among multiple studies ostensibly testing the effects 
of HIV awareness due to varying reference groups. Conversely, we found mixed evidence for the 
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association between HIV treatment and smoking prevalence. Last, HIV immune/viral recovery 
was generally associated with reduced smoking prevalence (Appendix Table 5.6). 
2.3.2. Alcohol use 
Eight longitudinal analyses on alcohol use were reviewed (Table 2.2). In three analyses, 
conducted in China and the U.S., up to 46% of participants who received their HIV diagnosis 
reported pre/post decreases in the amount of alcohol used.35, 81, 108 However, almost half also 
reported no change and as much as 19% of the population increased drinking instead.35, 108 
Findings were dependent upon the target population; in a study of female sex workers (FSW) in 
Miami, US, HIV-positive participants were almost twice as likely as HIV-negative participants 
to reduce their alcohol use after receiving HIV testing.81 Three analyses examined the 
relationship between ART status and long-term alcohol consumption using longitudinal clinic 
visit data and found no significant associations.66, 74, 91 Finally, a few trajectory analyses found 
that ART non-adherence and HIV disease progression were associated with elevated alcohol use, 
compared to those who were ART adherent and those who did not have disease progression, 
respectively (median follow-up times ranged from 1 to 9 years).67, 83, 88 
The remaining 49 cross-sectional analyses on alcohol are described in Appendix Table 5.3. 
Unlike for smoking, a majority of studies on alcohol use were conducted outside of North 
America/Europe/Australia.11, 35, 51, 58, 64, 69, 72, 73, 76-78, 82, 84, 85, 87, 89, 92, 93, 95, 96, 98-100, 103-107 Only one 
available study had biomarker measures (blood levels of phosphatidylethanol).88 Findings were 
inconsistent across studies. For example, among 26 studies comparing alcohol use by HIV 
infection status, 12 showed positive associations (i.e., HIV-positive persons drank more), 7 were 
negative and 7 were null. 
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2.3.3. Dietary behavior 
Dietary behavior received the least research attention of the four CVD risk behaviors, with only 
two available longitudinal studies (Table 2.3).47, 109 One study used repeated measures of dietary 
intake among a sample of HIV-positive men, based on 3-day food diaries at study visits. Cluster 
analysis was used to classify participants into three general dietary patterns, which were 
compared on health outcomes including CD4 count and viral load. No meaningful differences in 
these outcomes were observed between groups.109 In contrast, another study used measured 
changes in self-rated healthy diet pre/post HIV diagnosis, finding that 60.4% of persons in HIV 
care reported making healthy changes to their diet following their HIV diagnosis.47 No relevant 
cross-sectional studies of dietary behavior were found in the review (Appendix Table 5.4). 
2.3.4. Sedentary behavior 
The same study above included the only available longitudinal analysis of sedentary behavior. 
Participants self-reported whether their engagement in “regular exercise” changed after receiving 
their HIV diagnosis; results indicated that 43.6% reported newly engaging in “regular exercise” 
after receiving their HIV diagnosis (Table 2.4).47 The other five analyses were cross-sectional 
and used highly disparate measures of sedentary behavior; three defined sedentary behavior 
using measures of time spent engaging in physical activity (e.g., vigorous or moderate activity) 
52, 57, 110, and two measured self-reported participation in exercise or sports programs.64, 111 
Results largely showed no association between HIV continuum stage and any measure of 
sedentary behavior. Allen et al. found that high ART adherence was associated with participation 
in an exercise program (Appendix Table 5.5).64 
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 Discussion 
In this study, we aimed to systematically review the available literature on the effects of being in 
various stages of the HIV continuum on CVD risk behaviors. Of the four CVD risk behaviors we 
reviewed, smoking and alcohol use received the most research attention. Among the available 
studies on smoking and alcohol use, we observed that outcomes were compared across each of 
the HIV continuum stages, but that there was substantial variability in study designs and reported 
results (Table 2.5). The evidence generally supports positive associations between being HIV-
infected versus HIV-uninfected and elevated smoking and alcohol risk, and positive associations 
between being aware versus unaware of one’s HIV-positive status and elevated smoking and 
alcohol risk. In contrast, being on HIV treatment was generally associated with reduced smoking 
and alcohol risk. Dietary and sedentary behaviors received little research attention, thus there is 
insufficient evidence to draw any conclusions (Table 2.6). Importantly, despite the fact that 
stress-coping hypotheses are commonly cited as a plausible underlying mechanism, almost none 
of the available studies directly tested whether stress explained the observed associations, with 
few exceptions.99 Some authors acknowledged the role of stress-coping implicitly by controlling 
for various measures of stress (e.g., physical or psychological symptoms of HIV) as covariates in 
the analytical model. However, since stress-coping hypotheses were rarely of primary interest, 
comparisons with results after adjusting for these specific variables were not presented. 
It is worth noting that findings varied even across analyses ostensibly focused on the same HIV 
continuum stage-CVD risk behavior relationship. It is possible that this variability signifies true 
differences in effects across populations. However, several likely methodological sources of 
variability should be considered. A major consideration is differences in the time-frame of 
observation. This was most clearly illustrated in the study of smoking trends among HIV-
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positive patients initiating HIV care, which found sharp decreases in smoking behavior three 
months after HIV care initiation that tapered off during follow-up from 3 to 12 months.62 Similar 
patterns were evident with respect to HIV diagnosis, where reductions in smoking and alcohol 
use pre/post HIV diagnosis decreased as the time since diagnosis increased.35, 36 In other words, 
those who made healthy behavior changes after diagnosis were increasingly likely to relapse 
over longer periods of follow-up. In a similar vein, the findings from analyses using pre/post 
behavior change measures were generally not consistent with those on behavior trajectories. 
Whereas healthy behavior change was found to be commonplace among pre/post measures, 
trajectory analyses found long-term behavior change to be rare, often characterizing the 
overwhelming majority of participants as, e.g., persistent non-smokers or persistent heavy 
smokers.38 These trends may also be explained by time-frame of observation, since studies of 
pre/post behavior change typically measured behaviors more proximate to the event of interest, 
either HIV diagnosis or treatment initiation. It is known that these HIV care milestones heighten 
the salience of one’s own health vulnerabilities and increase contact with the health system, each 
of which could impact health behavior motivations;62 however, these phenomena would exhibit a 
recency effect as individuals become accustomed to their new circumstances.46, 62 Whether these 
HIV care milestones constitute “teachable moments” that are more amenable to behavior 
modification intervention remains an area of active research.62, 112 
Further uncertainty stems from ambiguity in how HIV continuum stage was defined, as a result 
of inadequate measurement or insufficient information provided. For example, HIV care or ART 
use status were often included as “covariates” in analytic models of behaviors by HIV status, but 
they may in fact be important determinants themselves. Indeed, observed associations varied by 
whether comparison groups captured differences in HIV infection, awareness of HIV infection or 
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treatment status. Disaggregating fully by HIV continuum stage would have helped clarify these 
differences, though some aspects are inevitably difficult to ascertain, such as determining time of 
HIV acquisition among persons newly diagnosed with HIV. 
Lastly, measuring lifestyle behaviors is inherently imprecise. CVD risk behaviors were most 
often self-reported; however this limitation may be fundamentally unavoidable for outcomes 
such as dietary intake for which no biomarker measures are currently available . Nonetheless, the 
few studies of smoking and alcohol that used biomarker confirmation did not yield qualitatively 
different results from those that did not.50, 62 Relatedly, detailed data such as the frequency or 
magnitude of a behavior was occasionally omitted or collapsed to binary variables in order to 
simplify data collection and analysis. Studies may yield different results if the granularity of 
measurement is important, e.g., if stress due to receiving an HIV diagnosis causes increases in 
binge drinking but does not cause increases in non-binge drinking. A number of studies used 
validated measures for alcohol use such as the Alcohol Use Disorders Identification Test 
(AUDIT) and its shortened form (AUDIT-C), but there remains significant variation across 
studies, and validated measures simply do not exist for some outcomes. 
Most of the studies were conducted in clinic-based or through convenience samples, which suffer 
from selection bias.28 Specifically, studies that aimed to assess behavior change after diagnosis 
among a sample of HIV care attending patients will necessarily exclude out-of-care populations 
who likely have lower health-seeking tendencies. Some studies also had strict exclusion criteria 
and/or high rates of non-participation, which would likely result in similar biases. In addition, 
most studies were conducted in resource-rich, predominantly urban settings, and therefore may 
not be generalizable to other populations due to differences in demographic compositions and 
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contextual risk factors.113 For example, several recent studies in the Multicenter AIDS Cohort 
Study and Women’s Interagency HIV Study (in the US and Europe) have found that risk 
behavior engagement is strongly predicted by race/ethnicity, economic stability and societal/peer 
norms, concepts that would likely differ in meaning and importance in other cultures.38, 114-116 
Thus, further research in other settings is essential for developing region-specific knowledge and 
interventions. Last, some studies were specifically targeted towards high HIV-risk populations 
(e.g., MSM, drug users or female sex workers) and their results would not be applicable to the 
general population. 
2.4.1. Strengths and limitations 
Our study has several key strengths and limitations. This is the first study to our knowledge to 
review the evidence of the effects of HIV on CVD risk behaviors.32, 117 We improved on the 
existing literature by explicitly disaggregating analyses by HIV continuum stage to examine 
patterns across stage. We also considered multiple CVD risk behaviors, hypothesizing that 
relationships would be similar across all CVD risk behaviors. Our review showed that findings 
were generally consistent between smoking and alcohol use, and that minimal research attention 
has been placed on dietary and sedentary behaviors to date. An important limitation is that in the 
process of stratifying our analysis by HIV continuum stage, the sample size of available studies 
was reduced for each comparison of interest. We expanded the review to include cross-sectional 
studies that were not designed specifically to examine the relationship between HIV and CVD 
risk behaviors; we expect that this would have broad impacts on each study’s target population, 
variable measurements and analytical choices, contributing to the disparate findings we 
observed. In addition, we excluded studies where the direction of causation was known to be in 
the opposite direction. As a result, studies that were unable to establish temporality were more 
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likely to be retained in the analysis, which may have introduced bias in the selection of studies 
for our review. 
 Conclusion 
Overall, our review provides modest support for causal effects of HIV infection and awareness 
and protective effects of HIV treatment and recovery on CVD risk behaviors, with the strongest 
and most consistent findings found for smoking compared to other CVD risk behaviors. Our 
findings suggest that the relationships differ by HIV continuum stage, though few studies 
operationalize HIV continuum stage adequately to answer this question. These findings have 
implications for clinical practice, as most individuals with HIV are diagnosed at advanced stages 
of HIV. Our review supports recent research suggesting that receiving an HIV diagnosis may 
indeed be a teachable moment, though evidence from intervention studies would be required to 
confirm whether efforts to translate intention to actual behavior change are effective and can be 
maintained over time.62 Future research is also required to ascertain the underlying mechanisms 
of the relationship, including directly testing whether stress explains the observed associations.  
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 Figures and Tables 
Figure 2.1 Systematic review flowchart 
 
Note: Sum of analyses by CVD risk behavior exceeds number of articles in full text review since some articles 





Table 2.1 Longitudinal analyses of smoking change by HIV continuum stage 
No. Author(s) (year) Location Population (n) Sampling 
Smoking 
measure(s) 
HIV continuum stage 

















HIV status (blood test) 
Persistent heavy smoking 
vs. non-smoking among 
HIV+ vs. HIV- 





use, marijuana use, 
hospitalizations, 
depression 
ART use (self-report: 
combined therapy) 
Persistent heavy smoking 
vs. non-smoking among 
ART users vs. non-users 
growth parameter* = 
0.0059 (p-value = 
NS) 
VL detectable (blood 
test) 
Persistent heavy smoking 
vs. non-smoking among 
undetectable vs. 
detectable VL† 
growth parameter* < 
-0.0001 (p-value = 
NS) 












(treat at CD4 <500 vs 
immediate) 
Smoking among 
immediate vs. deferred 
HIV treatment initiation 
β = -0.2 (-2.2, 1.7) baseline prevalence and visit 
3 Collins et al. (2001) 
United 
States 








Change in smoking after 
HIV diagnosis 
prevalence of 
reduced smoking = 
49% 
age, gender, ethnicity, 
marital status, 
education, drug use, 
CD4, symptom, self-
rated health, physical 
functioning, stress 
and coping 




and HIV- (n=400) 
women smokers  
Clinic-based 
Quit smoking 
since last visit 
(self-report) 
HIV serostatus (blood 
test) 
Quit smoking since last 
visit among HIV+ vs. 
HIV- 
















(self-report) HIV status (blood test: 
HIV+, HIV-, unknown 
status) 
Daily smoking among 
HIV+ vs. HIV- vs. 
unknown 
prevalence = 33.1% 
vs. 28.8% vs. 45.3%; 
(p=0.004) 
income, current self-
rated health, partner 
tobacco use, drinking 





among HIV+ vs. HIV- 
unadjusted mixed 
model RR = 2.10 
(0.87, 1.75) 

















Smoking trends over 
time since HIV care 
initiation 
prevalence every 3 
months after HIV 
care initiation = 
10%, 12%, 14%, 8% 
age, gender identity, 
race/ethnicity, 
education, work 









No. Author(s) (year) Location Population (n) Sampling 
Smoking 
measure(s) 
HIV continuum stage 
measure(s) Comparison Results Covariates adjusted 
















Change in smoking after 
HIV diagnosis 
prevalence = 28.9% 




Note: † denotes relationships that were transformed from the original publication to facilitate comparison across studies. 
* growth-specific parameters from group-based trajectory model 
Abbreviations: AACTG: Adult AIDS Clinical Trials Group, AIDS: Acquired Immune Deficiency Syndrome, ANC: Antenatal care, ART: Antiretroviral therapy, 
BMI: Body mass index, CO: Carbon monoxide, CVD: Cardiovascular disease, FSW: Female sex workers, HIV: Human immunodeficiency virus, IDU: Injection 
drug users, IeDEA: International Epidemiology Databases to Evaluate AIDS, MACS: Multicenter AIDS Cohort Study, MSM: Men who have sex with men, 
NHIS: National Health Interview Survey, OR: Odds ratio, PR: Prevalence ratio, RR: Risk ratio, SA NHANES: South Africa National Health and Nutrition 
Examination Survey, TB: Tuberculosis, VACS: Veterans Aging Cohort Study, VAS: Visual Analog Scale, VL: Viral load, VLS: Viral load suppression, WHO: 




Table 2.2 Longitudinal analyses of alcohol use change by HIV continuum stage 
No. Author(s) (year) Location 
Population 
(n) Sampling Alcohol measure(s) 
HIV continuum stage 
measure(s) Comparison Results Covariates adjusted 










use, past 6 months 
(self-report) 
ART adherence 0-
100%, past 6 months 
(MEMS) 
ART adherence among 
frequent vs. non-frequent 
alcohol use trajectories 
Mean adherence = 
37% vs. 62% 
(Kruskal Wallis 
p=0.09) 
not stated, possibly 
includes demographics, 
socioeconomic 
variables, HIV health, 
drug use VLS (blood test) 
VLS among frequent vs. 
non-frequent alcohol use 
trajectories 
Mean adherence = 
21% vs. 41% 
(Kruskal Wallis 
p=0.1) 










Started alcohol use, 
past 3 years (self-
report) 
Baseline VLS (blood 
test) 
Started alcohol use 
trajectory among VLS vs. 
not VLS at baseline 
adjusted multinomial 
OR = 0.9 (0.7, 1.2) 
age, race, clinical site Baseline CD4 category 
(<200, 200-350, 350+) 
(blood test) 
Started alcohol use 
trajectory among CD4 
>350 vs. <200 at baseline 
adjusted multinomial 
OR = 0.7 (0.5, 0.9) 











HIV care adherence, 
past 12 months (self-
report: no missed 
appointments) 
HIV care adherence by 
alcohol use CAGE score 
β=.03, p-value = 
0.019 
race, sexual orientation, 





drug use, HIV treatment 
intervention group 










Alcohol use, past 
month (self-report) HIV status (blood test) 
Alcohol use among HIV+ 
vs. HIV- pre/post HIV 
testing 
prevalence = 82.0% 
vs. 77.4%; p-value = 
NS 
unadjusted 









Alcohol use level HIV+ status known 
Change in alcohol use 
pre/post known HIV+ 
status 
% decreased = 
46.7%, % increased 
= 18.6%, % no 
change = 22.8%, % 




report: AUDIT-C - 
severe chronic, 
severe nonchronic, 
late onset, young 
adult) 
HIV status (blood test) Alcohol use trajectory among HIV+ vs. HIV- 
prevalence severe 
chronic = 47.8% vs. 
52.2%; prevalence 
severe nonchronic = 
43.5% vs. 56.5% (p-
value = .083) 

















Moderate vs. low/no 




(blood test: ≥200 
copies/ml) 




adjusted OR = 0.55 
(0.47, 0.64) 
race, income, age, 
probable depression, 





No. Author(s) (year) Location 
Population 
(n) Sampling Alcohol measure(s) 
HIV continuum stage 





trajectory model) Cumulative ART 
exposure, years (self-
report) 
Moderate alcohol use 
trajectory by cumulative 
ART exposure 
adjusted OR = 1.02 
(1.00, 1.05) 
risk score 
Low CD4 <300 vs. 
≥500 (blood test) 
Moderate alcohol use 
trajectory among low vs. 
high CD4 count 
adjusted OR women 
= 0.57 (0.45, 0.72); 
adjusted OR men = 
0.46 (0.38, 0.55) 
















measures used to 
classify high vs. 
moderate risk) 
HIV disease severity 
(VACS index: high or 
extreme vs. moderate) 
HIV disease severity (high 
or extreme vs. moderate 
severity) among high (vs. 
moderate) alcohol use 
trajectories 
adjusted OR (high 
disease severity) = 
1.21 (0.89, 1.63); 
adjusted OR 
(extreme) = 1.83 
(1.21, 2.78) 
demographics, HAART 
at baseline, CD4, VL, 
HCV, smoking, IDU, 
depressive symptoms, 
homelessness 










Heavy alcohol use, 
past 12 months 
(self-report: 
AUDIT-C >4 [men] 
or >3 [women] out 
of 12) 
HIV care retention, 
past 12 months 
(medical records: IOM 
definition & visit 
adherence proportion) 
HIV care retention among 
heavy vs. no drinking 
trajectories 
adjusted OR = 0.78 
(0.69, 0.88) 
drug use, panic 
symptoms, depression 
screen, sexual risk, age, 
race, IDU, CD4, VL, 
enrollment date, clinical 
site, panic symptoms 
and depression 
Visit adherence among 
heavy vs. no drinking 
trajectories 
adjusted OR = 0.97 
(0.91, 1.04) 








Change in alcohol 
use after HIV 
diagnosis (self-
report: increased vs. 
reduced vs. quit) 
HIV diagnosis (self-
report) 
Change in alcohol use 
pre/post HIV diagnosis 
prevalence = 45.4% 
reduced, 19.5% quit, 
2.5% increased age, sex, ethnicity, education, household 
income, employed ART use (self-report) 
Reduction in alcohol use 
reduction among ART 
users vs. non-users 
adjusted OR = 1.69 
(1.30, 2.18) 





Table 2.3 Longitudinal analyses of dietary behavior change by HIV continuum stage 




stage measure(s) Comparison Results 
Covariates 
adjusted 
1 Collins et al. (2001) 
United 
States 










Change in healthy diet 
pre/post HIV diagnosis 
sampling-weighted 
prevalence positive 
change in healthy 






















vs. fast food vs. 
fruit/veg) 
log(VL) (blood test) log(VL) by dietary intake pattern 
juice/soda vs. fast 
food dietary pattern: 
mean: mean log(VL) 
= 3.0 vs. 3.4; 
pairwise t-test 
p=0.008 
age, race, energy 
intake per kilogram 
CD4 count (blood 
test) 
CD4 count by dietary 
intake pattern 
ANOVA p-value = 
NS 
 
Table 2.4 Longitudinal analyses of sedentary behavior change by HIV continuum stage 





stage measure(s) Comparison Results 
Covariates 
adjusted 
1 Collins et al. (2001) 
United 
States 









Change in regular 




change in regular 















Table 2.5 Summary of study characteristics for all CVD risk behaviors 
 CVD risk behavior 
 Smoking Alcohol use Poor diet Sedentary 
No. studies 30 (100%) 54 (100%) 2 (100%) 6 (100%) 
Design     
Longitudinal 7 (23%) 8 (15%) 2 (100%) 1 (17%) 
Cross-sectional 23 (77%) 46 (85%) 0 (0%) 5 (83%) 
Sampling     
Population-based 4 (13%) 5 (9%) 0 (0%) 1 (17%) 
Hospital-/clinic-based 24 (80%) 35 (65%) 2 (100%) 4 (67%) 
Community-based 1 (3%) 6 (11%) 0 (0%) 0 (0%) 
Respondent-driven 1 (3%) 6 (11%) 0 (0%) 0 (0%) 
Convenience 0 (0%) 2 (4%) 0 (0%) 1 (17%) 
Region     
North America, Europe, Australia 22 (73%) 22 (41%) 2 (100%) 3 (50%) 
Sub-Saharan Africa 3 (10%) 21 (39%) 0 (0%) 1 (17%) 
South/Central America 0 (0%) 5 (9%) 0 (0%) 2 (33%) 
Asia 4 (13%) 6 (11%) 0 (0%) 0 (0%) 
Multiple 1 (3%) 0 (0%) 0 (0%) 0 (0%) 
CVD risk behavior measures     
Biomarker 3 (10%) 1 (2%) 0 (0%) 0 (0%) 
Self-report 27 (90%) 52 (96%) 2 (100%) 6 (100%) 





Table 2.6 Summary of findings of longitudinal studies for all CVD risk behaviors 
 CVD risk behavior 
 Smoking Alcohol use Poor diet Sedentary 
HIV continuum stage     
HIV infection + (n=3) + (n=2) No studies No studies 
HIV awareness M (n=2) − (n=1) No studies No studies 
HIV treatment − (n=2) M (n=4) − (n=1) − (n=1) 
HIV immune/viral recovery No studies − (n=1) 0 (n=1) No studies 
Note: This table summarizes the findings of the systematic review for each CVD risk behavior by HIV continuum stage 
comparison. Effect estimates were harmonized across studies to enable comparisons (i.e., associations were reversed if variables 
were reverse-coded in a given study). Symbols indicate the predominant direction of association observed for all studies of that 




 PATTERNS OF CARDIOVASCULAR DISEASE RISK BEHAVIORS 
ACROSS THE HIV CONTINUUM: DATA FROM A POPULATION-BASED STUDY 
OF OLDER ADULTS IN RURAL SOUTH AFRICA 
 Abstract 
Background: Mounting qualitative evidence suggests that people living with HIV (PLWH) 
adopt unhealthy cardiovascular disease (CVD) risk behaviors as a way to cope with the stress of 
living with HIV. However, few quantitative studies have been conducted to assess whether HIV 
causes adoption of CVD risk behaviors, let alone whether stress mediates this relationship. This 
study aimed to explore the patterns of three CVD risk behaviors, smoking, hazardous alcohol use 
and sedentary behavior across stages of the HIV continuum (HIV-negative, HIV-positive and 
unaware, HIV-positive aware and untreated, HIV-positive on treatment). In secondary analyses, 
we assessed whether various types of HIV-related physiological and psychological stress 
mediated the observed relationships. 
Methods: Analyses were conducted using baseline data from a population-based cohort study of 
adults 40 years and older in rural Agincourt district in South Africa. HIV infection status was 
defined using dried blood spot HIV tests, and, among HIV-positive individuals, awareness and 
treatment status were defined using self-reported HIV status and detectable antiretroviral (ARV) 
drugs, respectively. CVD risk behaviors were defined using self-reported current smoking, 
hazardous alcohol use and sedentary behavior. Potential mediators of the relationship between 
HIV continuum stage and CVD risk behaviors included symptoms such as muscle weakness 
measured via grip strength test, and self-reported pain, physical dysfunction, cognitive 
impairments, and measures of psychological stress such as depressive symptoms and low 
subjective well-being. We estimated prevalence ratios (PR) and 95% confidence intervals (CI) 
for each CVD risk behavior across HIV continuum stage, in total and sex-stratified models. We 
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then tested whether there was evidence for mediation by also adjusting individually for each 
proposed mediator. 
Results: A sample of n=4,061 participants were included in the study. The overall crude 
prevalence estimates of smoking, hazardous alcohol use and sedentary behaviors were 9%, 10%, 
and 30%, respectively. Compared to the HIV-negative group, the prevalence of smoking and 
hazardous alcohol use were both highest in the HIV-positive treated group: PR (95% CI) for 
smoking: 1.12 (0.66, 1.90); hazardous alcohol use: 1.10 (0.61, 1. 96). The prevalence of 
sedentary behavior was highest in the HIV-positive unaware group: 1.10 (0.96, 1.28). None of 
these findings were statistically significant. We found no evidence of mediation, as none of the 
hypothesized mediators appreciably changed any effect estimates after controlling in adjusted 
models. 
Discussion: The results of this study demonstrated that CVD risk behaviors were not 
significantly differently distributed across HIV continuum stage. Findings do not support the 
hypothesis that physiological and/or psychological stress mediates the relationship between HIV 





Since the introduction of antiretroviral therapy (ART), the survival of people living with HIV 
(PLWH) on treatment has approached that of the general population.1 However, while total 
mortality has decreased, the proportion of deaths due to cardiovascular disease (CVD) has 
increased.2-5 Numerous studies have shown that this is partly due to high prevalence of CVD risk 
behaviors among PLWH.6-15 As a result, CVD prevention has become a health priority for HIV-
positive populations, and treatment guidelines now recommend that clinicians routinely advise 
all HIV-positive persons to maintain a healthy lifestyle16, which consists of avoiding smoking 
and hazardous alcohol use, minimizing unhealthy diet and adopting more active lifestyles.17 
CVD risk behaviors are of particular interest for older individuals living with HIV, since CVD is 
strongly associated with age.18 Furthermore, older individuals comprise a fast-growing segment 
of the HIV-positive population, due to longer survival of PLWH on ART. As well, data 
demonstrate that such older populations remain at high risk of HIV acquisition due to failure of 
HIV prevention services to focus on this group and their having lower condom use and HIV 
testing rates as compared to younger people.19-22 These trends are especially notable in the sub-
Saharan African (SSA) region, which has the highest burden of HIV in the world and is 
undergoing drastic urbanization, associated with increases in sedentary behaviors and diets 
higher in processed foods.23, 24 Currently, most HIV research and programs focus on adolescents 
and younger adults of reproductive age; thus further research on CVD risk behaviors among 
older PLWH in SSA is needed. 
An important unresolved question is how HIV and CVD risk behaviors are related. CVD risk 
behaviors are frequently shown to be more prevalent among HIV-positive populations than the 
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general population.12, 25-29 These differences often remain after controlling for known 
demographic and socioeconomic confounders, and have been replicated to varying degrees 
across populations. Yet, the underlying reasons have not been well-established. Unhealthy 
behaviors may operate as both antecedents and consequences of HIV, and much of the existing 
evidence is based on cross-sectional data, which cannot differentiate between the two pathways. 
Despite this, authors typically emphasize the role of CVD risk behaviors, particularly smoking 
and alcohol use, as antecedents of HIV. A growing body of qualitative evidence points, however, 
to the possibility that unhealthy behaviors can occur in response to HIV as a stress-coping 
mechanism, offering another plausible explanation. Put simply, PLWH often report feeling 
overwhelmed after receiving their HIV diagnosis30-33 and adopting unhealthy behaviors as a form 
of relief or distraction from the stress of living with HIV.34-37 In this context, HIV-related stress 
encompasses both the physiological symptoms of HIV, including pain38, weakness, physical 
dysfunction39-41, cognitive impairments42, 43, as well as its psychological symptoms, such as 
depressive symptoms44, 45 and diminished subjective well-being.a While this is not an exhaustive 
list, it illustrates the profound physiological and psychological burdens that being HIV-positive 
can impose on an individual.46, 47 Each of these is known to predict unhealthy behavior 
engagement in other disease contexts.48, 49 Therefore, HIV-related stress, defined here as the 
physiological and psychological symptoms of HIV, may partly account for the elevated 
prevalence of CVD risk behaviors among PLWH and explain why they often persist despite 
intensive behavior modification efforts.9, 50-52 
                                                 
a The stress-coping theoretical framework is presented only briefly here but explicated in full 
detail in Chapter 1. 
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Under a stress-coping hypothesis, these physiological and psychological forms of stress would 
potentially act as mediators of a causal effect of HIV on CVD risk behaviors. Such mediation 
analyses may elucidate the underlying mechanisms and may also uncover clues regarding 
temporality. To illustrate, individuals may experience the physiological symptoms of HIV 
whether they are aware of their status or not; therefore, mediation pathways through 
physiological symptoms can plausibly operate among all HIV-infected individuals. In contrast, 
individuals can only experience psychological distress as a result of their infection after they 
know or suspect that they are HIV-positive; therefore, psychological stress-coping mechanisms 
can only operate among HIV-positive individuals who are aware of their status. Similarly, HIV-
positive individuals who are on treatment, based on evidence of the salutary effects of ART on 
health and well-being of PLWH, would be expected to experience fewer physiological and 
psychological symptoms than those who are off treatment; therefore, both physiological and 
psychological stress-coping pathways would be attenuated among treated versus untreated 
individuals. 
Assuming a mediation hypothesis is true, this suggests that physiological and psychological 
stress-coping pathways would operate differently at different stages of an HIV continuum that 
characterizes HIV infection, awareness and treatment status. Importantly, heterogeneity in 
outcomes would be obscured when using dichotomous measures, as has often been used in prior 
research (see Figure 3.1). Under the strong assumption that baseline CVD risk behaviors are 
similar across stages, observed differences in behavior prevalence by HIV continuum stage may 
be at least partly attributable to the consequences of HIV infection, awareness of infection and 
being on treatment, whereas lack of differences by stage would suggest against a mediation 
hypothesis. Thus, the HIV continuum approach may help disentangle mediation vs. confounding 
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pathways. Accordingly, we hypothesize that CVD risk behaviors would be least prevalent among 
HIV-negative individuals and most prevalent among HIV-positive individuals who are aware of 
their status but not on treatment. 
To address these knowledge gaps, we explored the relationships between HIV continuum stage 
and three CVD risk behaviors among a population-based cohort of adults aged 40 years and over 
in rural Agincourt district in South Africa. As a secondary objective, we examined the potential 
mediating role of several measures of physiological and psychological stress in this relationship. 
 Methods 
3.3.1. Data source 
This study used baseline data from the Health and Aging in Africa: A Longitudinal Study of an 
INDEPTH Community in South Africa (HAALSI) study. The HAALSI study was designed to 
explore the individual, economic and contextual determinants of aging-related health conditions 
and overall well-being of older adults in a high HIV prevalence area. Recruitment was nested 
within the Agincourt Health and Demographic Surveillance System, from which a population-
representative, sex-stratified random sample of 6,281 adults aged 40 years and over was drawn. 
One-fifth of sampled individuals were unable to or refused to participate in the study, yielding a 
total of n=5,059 participants who enrolled in the baseline cohort. This sample constituted 
approximately 20% of all eligible adults residing in Agincourt district at the time of 
recruitment.53 
A survey questionnaire and physical examination were conducted and dried blood spot (DBS) 
samples were obtained from participants. Survey instruments were translated from English to the 
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local Shangaan language and back-translated to verify accuracy. Trained fieldworkers collected 
survey data using an interviewer-administered computer-assisted personal interview system on 
electronic tablets. Data were collected between November 2014 and November 2015 and have 
been made publicly available on the Harvard Dataverse website.54 HAALSI was conducted by an 
interdisciplinary team of investigators at the Harvard School of Public Health and University of 
Witwatersrand in South Africa and ethical approvals were provided by each institution’s IRB 
and the Mpumalanga Provincial Research and Ethics Committee. Eligibility for this analysis was 
restricted to individuals who consented to DBS testing and had complete data on all analytic 
variables described below (Figure 3.2). 
3.3.2. Measures 
The main exposure was defined in two ways. Firstly, we created a dichotomous measure of HIV 
status (HIV-positive vs. HIV-negative) using results from DBS HIV testing. Secondly, we 
created a categorical HIV continuum stage variable (HIV-, HIV-positive but unaware, HIV-
positive aware and untreated, and HIV-positive on treatment) using a combination of DBS HIV 
test results, detectable antiretroviral (ARV) drug levels (DBS samples were tested for FTC or 
3TC as these two ARVs were used in all first and second-line ART regimens in South Africa at 
the time of the study), and self-reported lifetime diagnosis of HIV. HIV viral load results 
(dichotomized as >100 vs. ≤100 log10 copies/ml) were used for sensitivity analyses by virologic 
suppression status among the HIV-positive on treatment group (see below). 
Outcomes included three self-reported CVD risk behaviors, smoking, hazardous alcohol use and 
sedentary behavior. Smoking was defined using the question “Do you currently smoke any 
tobacco products, such as cigarettes, cigars or pipes?” Hazardous alcohol use was defined using 
 
 55 
the Alcohol Use Disorders Identification Test (AUDIT-C), a screening tool that distinguishes 
hazardous from non-hazardous alcohol use based on self-reported alcohol use frequency, severity 
and binge drinking and has been validated in low-income settings.55, 56 Hazardous alcohol use 
was classified using scores of >4 or >3 out of 12 total points for men and women, respectively, 
as per established guidelines.55, 56 Sedentary behavior was defined using the International 
Physical Activity Questionnaire (IPAQ) score, a screening tool that classifies an individual’s 
weekly physical activity level based on self-reported time spent doing vigorous or moderate 
physical activity or walking .57, 58 Participants were classified as sedentary if they failed to meet 
any of the following criteria: 3+ days of vigorous activity at least 20 minutes per day, 5+ days of 
moderate activity or walking at least 30 minutes per day, or 5+ days of any combination of 
vigorous or moderate activity or walking achieving 600+ MET-minutes per week. IPAQ has 
been validated in low-income settings.58 See Appendix Tables 5.7 and 5.8 for full details of 
AUDIT-C and IPAQ survey questions and scoring algorithms. 
Potential mediators included four measures of physiological stress and two measures of 
psychological stress. Muscle strength was measured via grip strength tests performed in each 
hand. Scores were averaged across hands and used to classify muscle weakness using validated 
clinical thresholds for men and women (<37 kg and <23 kg, respectively).59 Pain was assessed 
using the Brief Pain Inventory (BPI), a validated 11-item screening tool based on four questions 
regarding severity of pain in the past 24 hours and seven questions regarding the degree to which 
pain interferes with daily activities, each on a scale of 0-10.60, 61 Mean scores were calculated 
separately for the severity and interference sub-scales and participants. Individuals with mean 
scores of 4 or greater on either sub-scale were classified as experiencing difficulties with pain. 
Physical dysfunction was defined as having difficulties performing activities of daily living 
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(ADLs) using the Katz Index of Independence in ADLs. Participants reported whether they could 
perform each of six ADLs (walking, sleeping, eating, bathing, getting in and out of bed, and 
using the toilet) without difficulties or assistance. Those who reported having difficulties or 
required assistance with at least one ADL were classified as experiencing physical dysfunction. 
Cognitive impairment was defined as having self-reported difficulties with memory, 
concentration, or learning new tasks. Each item was assessed using 5-point Likert scales, and 
individuals who reported having either fair/poor memory or moderate/severe/extreme difficulties 
with concentration or learning new tasks were classified as having cognitive impairments. 
Two measures of psychological stress were defined as follows. We assessed depressive 
symptoms using the 8-item Center for Epidemiological Studies Depression scale (CESD-8), 
which is a widely used screening tool that has been validated in sub-Saharan African settings.62-
65 Scores of >4 out of 8 total points were classified as elevated depressive symptoms. Lastly, low 
subjective well-being was assessed using two questions on life satisfaction “…how satisfied are. 
you with your life as a whole these days?” and self-evaluated quality of life “Please imagine a 
ladder… Suppose we say that the top of the ladder represents the best possible life for you and 
the bottom represents the worst possible life for you. On which step of the ladder would you say 
you personally feel you stand at this time?” Both items were rated on 0-10 scales, the average of 
which was used as the subjective well-being score. Scores of ≤5 were classified as low subjective 
well-being. See Appendix Table 5.9 for detailed information on each survey question. 
Potential confounders included demographic characteristics such as sex, age (continuous), 
education (completed primary education vs. lower educational attainment) and wealth (poorest 
40% vs. other, using a household-based wealth index). In addition, variables on CVD history 
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were considered, including self-reported lifetime diagnosis or treatment for hypertension, 
dyslipidemia, diabetes, and self-reported lifetime occurrence of any of four cardiovascular 
events: myocardial infarction, stroke, angina or heart failure. 
3.3.3. Analysis 
We described sample characteristics for all analytic variables. We then assessed the relationships 
between HIV status and each CVD risk behavior by fitting log-Poisson regression models to 
estimate prevalence ratios (PR) and 95% confidence intervals (CI) (generalized linear model 
with log link, Poisson distribution and robust standard errors).66, 67 We further compared CVD 
risk behavior patterns by HIV continuum stage to assess if additional information was gained by 
stratifying by awareness and treatment status. We found that self-reported smoking and alcohol 
use was very low among females and thus also ran models stratified by sex. 
In order to identify potential confounders, we constructed directed acyclic graphs (DAGs) for 
each of the hypothesized causal relationships to determine the minimal set of potential 
confounders sufficient for adjustment. Potential confounders were verified analytically using a 
p<0.10 threshold for significance and then included in models to estimate adjusted PRs (see 
Appendix Table 5.10 for bivariate analyses between each potential confounder and each 
exposure category and outcome). Unadjusted and adjusted analyses were compared to assess the 
degree of bias due to confounding. 
We then examined whether there was evidence for mediation via each hypothesized mediator. 
Using standard mediation analysis methods, we first tested the significance of each of the 
exposure-mediator and mediator-outcome relationships (i.e., the indirect pathways).68 We then 
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estimated direct effects by comparing point estimates from the adjusted models above (total 
effects) with models additionally adjusting for each proposed mediator (direct effects). Point 
estimates that moved towards the null were considered consistent with a mediation hypothesis. 
All analyses were performed using Stata version 15.1 (Stata Corp, College Station, TX, USA). 
3.3.4. Sensitivity analyses 
Missing data. We were unable to determine HIV continuum stage among 9% of participants, 
primarily due to refusal to provide DBS specimen (n=352, 7%). Missing data on survey variables 
was minimal, since surveys were administered using electronic tablets which forced responses. 
Nonetheless, missing data were observed among 2-3% of participants on variables related to 
subjective well-being, pain and cognitive impairment variables, as a result of “don’t know” or 
“refused” responses. Data on muscle weakness were also missing for 7% of participants who did 
not complete the physical exam. We explored the impact of missing data by conducting 
sensitivity analyses using multiple imputation (MI) via chained equations to impute missing 
values. We elected not to impute missing HIV status since it is well-documented that individuals 
who know they are HIV-positive have been noted to be more likely to refuse testing, thus 
missing data were unlikely to meet the requisite missing at random assumption.69 Sample 
characteristics were compared between the “complete case sample” used in main analyses 
(n=4,061) and those missing data only on HIV continuum stage, referred to hereafter as the “MI 
sample” (n=4,610). We then examined whether the results from complete case and MI analyses 
substantially differed. 
Exposure operationalization. We also explored whether results were sensitive to how HIV 
continuum stage was operationalized. Results of the main analysis were compared to those from 
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three scenarios using alternative exposure definitions. In scenario 1, we aimed to address the 
potential for known HIV-positive individuals to falsely report being HIV-negative. Individuals 
who were initially classified as HIV-positive and unaware but who had reported having their last 
HIV test six or more months previously and had a detectable HIV viral load test (>2 log10 
copies/mL) were assumed to in fact know their status. We re-classified these individuals from 
HIV-positive unaware to HIV-positive aware untreated and compared results. In scenario 2, we 
used self-reported ART use as well as detectable ARVs to classify individuals as HIV-positive 
on treatment. Compared to detectable ARVs alone, this more inclusive measure of treatment 
status aimed to account for possible momentary ART non-adherence at the time of the test. In 
scenario 3, we explored whether failure to achieve viral suppression among those with detectable 
ARVs was associated with unhealthy behaviors, since those experiencing treatment failure may 
feel sicker than those whose virus is suppressed. We examined whether outcomes among the 
HIV+ on treatment group varied by viral suppression (<2 log10 copies/ml), which was achieved 
by 72% of those with detectable ARVs. 
 Results 
3.4.1. Participant characteristics 
Of the n=4,061 participants in this study, 46% were male, 52% were over age 60, and less than 
one-fifth completed primary education or were employed (Table 3.1). HIV prevalence was 25%, 
though only 17% self-reported being HIV+. Among those who tested HIV-positive, 64% had 
detectable ARVs. These data showed that 3,038 (75%) were in the HIV-negative group, 275 
(7%) were in the HIV-positive unaware group, 93 (2%) were in the HIV-positive aware 
untreated group, and 655 (16%) were in the HIV-positive on treatment group. The overall 
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prevalence estimates of smoking, hazardous alcohol use and sedentary behavior were 9%, 10%, 
and 44%, respectively. Over one-third of participants self-reported awareness of hypertension 
diagnosis, 13% dyslipidemia diagnosis and 7% diabetes diagnosis. The most prevalent symptoms 
reported were muscle weakness (66%), cognitive impairments (42%) and low subjective well-
being (29%). Differences by sex were notable for smoking and hazardous alcohol use, which 
were reported by very few women. Some covariates such as being married and experiencing 
muscle weakness were also more common among men. 
3.4.2. CVD risk behavior patterns 
Overall sample. Table 3.2 shows PRs and 95% CIs for each CVD risk behavior by HIV status. 
In unadjusted analyses, HIV-positive versus HIV-negative status was associated with higher 
prevalence of smoking: PR (95% CI) = 1.23 (1.03, 1.46); no difference in hazardous alcohol use: 
1.00 (0.83, 1.21); and lower prevalence of sedentary behavior: 0.85 (0.78, 0.93). Bivariate 
analyses showed that sex, age, education, employment, marital status, wealth, hypertension, 
dyslipidemia and diabetes all met criteria for confounding and were thus included as confounders 
in all analyses (Appendix Table 5.10). After adjusting for confounders, the association between 
HIV+ status and smoking was attenuated and no longer statistically significant: PR (95% CI) = 
1.10 (0.90, 1.34), and the associations between HIV+ status and hazardous alcohol use and 
sedentary behaviors did not change: 0.95 (0.78, 1.15) and 0.89 (0.81, 0.97), respectively.  Table 
3.2 also shows PRs and 95% CIs for each CVD risk behavior by HIV continuum stage, using the 
HIV-negative group as the reference category. We found that the HIV-positive aware untreated 
group had the highest prevalence of smoking and hazardous alcohol use, though none of the 
associations reached statistical significance in unadjusted or adjusted models. The HIV-positive 
on treatment group had the lowest prevalence of sedentary behaviors in unadjusted analyses: PR 
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(95% CI) = 0.79 (0.70, 0.88), but this association did not remain significant in the adjusted 
model. Predicted prevalence estimates are calculated from the regression model after adjustment 
for confounders and displayed in Figure 3.3. 
Sex-stratified models. Results from sex-stratified models showed that effect estimates among 
males were generally similar to those among all participants. Compared to the HIV-negative 
reference group, the prevalence of smoking was significantly higher in the HIV-positive aware 
untreated group: PR (95% CI) = 1.64 (1.01, 2.67), and the prevalence of hazardous alcohol use 
was higher in the HIV-positive unaware group: 1.45 (1.00, 2.09), but these associations did not 
remain significant in adjusted analyses. Among females, there were almost no self-reported 
smokers in the HIV-positive unaware and HIV-positive aware untreated groups thus PRs for 
smoking were both 0.0. In adjusted analyses, the HIV-positive aware untreated group had the 
highest prevalence of hazardous alcohol use: PR (95% CI) = 2.72 (1.04, 7.09). Predicted 
prevalence estimates are displayed graphically in Figure 3.4 by males and females (numerical 
results are reported in Appendix Table 5.11). 
3.4.3. Mediation analyses 
The unadjusted prevalence of each hypothesized mediator is reported in Table 3.3 by HIV 
continuum stage and outcome status. Contrary to our hypothesis, none of the proposed mediators 
were more common among HIV-positive versus HIV-negative groups. Furthermore, the 
prevalence of each proposed mediator was generally similar among HIV-positive groups, 
irrespective of awareness or treatment status. However, these patterns reversed after controlling 
for age (data not shown). Muscle weakness was associated with higher prevalence of smoking 
and hazardous alcohol use, but the other proposed mediators were either inversely associated or 
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not associated with smoking. All proposed mediators were positively associated with sedentary 
behavior. 
 
Results from mediation analysis models are reported in Table 3.4 and displayed graphically in 
Figure 3.5. Total effects (using adjusted models above) were not statistically significant prior to 
testing for mediation, and point estimates did not change appreciably after controlling for any 
physiological or psychological symptom. 
3.4.4. Sensitivity analyses 
Sensitivity analyses using MI demonstrated no significant changes in point estimates or CIs as 
compared to the main analysis among complete cases only (Table 3.5). Results from the three 
alternative exposure definitions scenarios are shown in Table 3.6. The main analysis represents 
the adjusted model above. In scenario 1, we re-classified 21 individuals from being HIV-positive 
unaware to HIV-positive aware untreated based on having received HIV testing at least 6 months 
prior to the study and a detectable viral load; results were not appreciably different from the base 
case model. In scenario 2, we re-classified 45 individuals from being HIV-positive aware 
untreated to HIV-positive on treatment based on self-reported ART use. Smoking and hazardous 
alcohol use were no longer highest in the HIV+ aware untreated group, though the revised 
estimates remained non-significant. Finally, in scenario 3 we generated a new category for 
virally suppressed, which included 484 individuals. Results differed slightly between the HIV-
positive on treatment and HIV-positive virally suppressed groups; notably, the HIV-positive on 
treatment (non-suppressed) group was associated with higher smoking and HIV-positive virally 
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suppressed group was associated with lower smoking. However, none of the observed 
differences were statistically significant before or after stratifying by viral suppression. 
 Discussion 
In this study, we examined the relationships between HIV and three CVD risk behaviors among 
a rural sample of older adults in South Africa. We found that HIV continuum stage was not 
significantly associated with smoking, hazardous alcohol use or sedentary behaviors. However, 
point estimates of the prevalence of smoking and hazardous alcohol use were highest among 
individuals in the HIV-positive aware untreated group, which is consistent with our a priori 
hypothesis that this group would be most likely to engage in unhealthy behaviors. Comparing 
HIV-positive versus HIV-negative individuals, i.e., ignoring awareness and treatment status as is 
often done in other studies, we observed that HIV infection status was not significantly 
associated with smoking and hazardous alcohol use and associated with lower prevalence of 
sedentary behaviors. These findings are not consistent with prior studies, which have generally 
observed drastically elevated CVD risk behaviors among HIV-positive versus HIV-negative 
individuals.6-15, 25-29 However, while our results did not achieve statistical significance, point 
estimates suggest 10% increased prevalence of smoking among HIV-positive versus HIV-
negative individuals. 
Some findings varied by sex of the participants. However, differences by sex were largely driven 
by extremely low overall prevalence of smoking and hazardous alcohol use among women. In 
our sample, 20% of men and <1% of women self-reported smoking; thus the model for smoking 
among women was largely uninformative. Likewise, hazardous alcohol use was reported by 16% 
of men and only 4% of women. Patterns of hazardous alcohol use across HIV continuum stage 
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differed by sex, with highest prevalence being observed in the HIV-positive aware untreated 
group among women, and in the HIV-positive unaware group among men. It remains unclear 
why alcohol use patterns differed between men and women, though it is possible that men’s and 
women’s behavioral responses to HIV differ in this setting. However, since baseline prevalence 
was higher among men, larger relative differences in outcome prevalence by HIV continuum 
stage would have been necessary for significant findings to emerge among men than women.  
The overall and sex-stratified CVD risk behavior prevalences observed in our study are similar to 
other population-based studies conducted in this setting. The first South Africa National Health 
and Nutrition Examination Survey (SA NHANES) estimated an overall smoking prevalence of 
15.3% (95% CI: 12.0%, 19.4%) in Mpumalanga Province, with 28.7% (22.9%, 35.3%) among 
males and 3.6% (2.2%, 5.8%) among females.70 Similarly, the South African National HIV, 
Incidence, Behaviour and Communication (SABSSM) 2008 survey. estimated the prevalence of 
hazardous alcohol use to be 9% (Males: 17%; Females: 2.9%).71 Nationally-representative data 
from the Global Ageing and Adult Health (SAGE) survey in South Africa found that 42% of 
adults 18 years or older were sedentary (defined as physically inactive using the Global Physical 
Activity Questionnaire)72, similar to 47% overall prevalence of sedentary behavior in this study. 
However, unlike in the current study, significant differences were found by HIV status. One 
study conducted among chronic care patients in North West Province, South Africa estimated the 
prevalence of hazardous alcohol use to be 12.9% vs. 6.0% among HIV-positive vs. HIV-negative 
individuals.73 One explanation is that previous studies may have been biased by restricting 
participation to clinic-based samples. In addition, these studies were not restricted to older 
adults; thus, our null findings may simply reflect unique characteristics of the aging population 
in this setting. 
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In mediation analyses, the patterns of proposed mediators across HIV continuum stages were not 
consistent with what we hypothesized a priori. We expected to see greater physiological 
symptoms between HIV-positive vs. HIV-negative individuals, and greater psychological 
symptoms between HIV-positive aware vs. unaware individuals. In fact, all proposed mediators 
(i.e., muscle weakness, pain, physical dysfunction, cognitive impairment, depressive symptoms 
and low subjective well-being) were either less prevalent or no different between HIV-positive 
vs. HIV-negative groups, irrespective of awareness and treatment status. Since it is unlikely that 
HIV acquisition or diagnosis alleviates these symptoms, this suggests that they were likely to be 
antecedents, rather than consequences, of HIV acquisition. For example, those experiencing pain 
and weakness may have been less sexually active and thus had lower risk of acquiring HIV. This 
hypothesis is further supported by the fact that most symptoms as measured in this study were 
associated with age – symptomatic individuals were more likely to be both older and HIV-
uninfected. 
The estimated prevalence ratios did not change appreciably after adjusting for any of the 
proposed mediators, failing to provide support for our mediation hypothesis. It is possible that 
residual biases may explain null findings if, for example, individuals with better self-care 
behaviors are more likely to seek HIV testing (confounding) or agree to participate in the study 
(selection). Critically, however, since the mediation pathways were expected to vary across HIV 
continuum stages, these biases would have also had to operate differentially by stage in the 
opposite direction in order to produce the null findings we observed. It is therefore unlikely that 
we would have observed these null findings if the mediation pathways did in fact exist via the 




First, the aforementioned temporality concerns regarding the exposure-outcome relationship 
equally apply to the mediator-exposure and mediator-outcome relationships. In addition, we 
cannot assume monotonic effects, i.e., HIV-related symptoms may encourage some individuals 
to adopt healthier behaviors rather than risk behaviors for CVD. If symptoms are causal in some 
individuals and protective in others, we would only observe net effects averaged across 
individuals, obscuring mediation effects. It is worth noting that several prior studies have tested 
the relationship between HIV and CVD risk behaviors and found that symptoms, such as 
depression, met statistical criteria for confounding.74-76 In these studies, the authors rarely 
described, let alone tested, these symptoms as potential mediators; however, to the extent that 
temporality could not be established, these findings could be consistent with confounding or 
mediation mechanisms. 
3.5.1. Limitations 
This study has several key limitations. First and foremost, the cross-sectional nature of the data 
hindered our ability to establish temporality of the relationships between exposures, mediators 
and outcomes. We addressed this limitation by hypothesizing specific mediation pathways that 
would operate differently for physiological and psychological symptoms across HIV continuum 
stages, and leveraging the inherent sequential ordering of the HIV continuum to help distinguish 
between mediation vs. confounding effects. Observed symptom patterns across stage were not 
consistent with our mediation hypothesis, but CVD risk behavior patterns suggested that 
accounting for awareness and treatment status yielded additional information. For example, 
compared to the HIV-negative group, smoking prevalence was estimated to be 40% higher in the 
HIV-positive aware untreated group but only 7% and 15% higher in the HIV-positive unaware 
and HIV-positive on treatment groups, respectively, findings that would have been missed if 
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comparing by HIV infection status alone. However, the sample sizes in this study were too small 
to detect even modest effect sizes across HIV continuum stage, especially since the prevalence of 
untreated infection is low among those who were aware of their HIV status. 
Second, the use of self-reported measures raises potential concerns with measurement error. We 
had no information on adherence or length of time since treatment initiation; thus, our definition 
of being on treatment assumes everyone on treatment was adherent and would have had 
detectable ARVs as per DBS testing. Additionally, HIV status may be underreported due to its 
sensitive nature and fear of stigma and discrimination. Sensitivity analyses found that few 
participants would have been re-classified based on several likely misclassification scenarios, 
and findings were not sensitive to such changes. 
Third, while the proposed mediators are known to be associated with HIV, at best they are 
proxies of HIV-related stress. Specifically, these variables represent various manifestations of 
HIV in the forms of physiological discomforts or disabilities, or negative cognitive or emotional 
states that are indicative of feeling stressed. However, the available measures were not HIV-
specific; thus, we could not determine whether individuals feeling depressed, for example, were 
depressed due to being HIV-positive or some other cause. We also lacked other likely stress-
coping pathways, notably via symptoms of anxiety or experiences or feelings of stigma. Ideal 
measures of stress could include salivary or hair cortisol levels, which quantify cumulative 
exposures to chronic stress.77 However, it would still be fundamentally difficult to determine 
whether the stress experienced by an individual actually prompted them to engage in unhealthy 




Fourth, about 20% of the overall cohort was not included in this study due to missing data, most 
notably the 7% who refused consent to participate in DBS testing. Fortunately, most other 
missing data were minimal, and while the distributions of most variables were significantly 
different between complete case vs. MI samples (the complete case sample was slightly younger 
and less symptomatic), most differences were within 2% and therefore not likely to have affected 
our findings (Appendix Tables 5.12 and 5.13). Sensitivity analyses comparing complete case and 
MI analyses did not suggest that selection bias was present. Point estimates and CIs from MI 
analyses were not meaningfully different from those in complete case analyses; nonetheless, this 
assumption cannot be tested empirically using the observed data. Potential for selection bias was 
likely mitigated by the population-based sampling approach, which ensured representation of 
uninfected, undiagnosed and out-of-care populations, who are often omitted by design in clinic-
based samples. 
Finally, we cannot rule out residual confounding from other predictors of HIV acquisition, 
testing and treatment, including health-seeking tendencies that would influence unhealthy 
behavior engagement and access to care. As a result, individuals at different HIV continuum 
stages may differ on other common causes of HIV-related stress and CVD risk behaviors that 
were not captured in this study. Other unmeasured contextual factors, including social norms and 
health messaging unique to this population and setting may also limit generalizability to other 
populations. 
 Conclusion 
This study explored the relationships between HIV and CVD risk behaviors among a population-
based sample of older adults living in a rural, high HIV prevalence area in South Africa. Our 
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findings provide evidence that CVD risk behaviors were not associated with HIV continuum 
stage among the older adult population, suggesting that behavioral modification interventions 
may be best targeted towards the general population. This study was also the first to our 
knowledge to conduct mediation analyses to test this stress-coping hypothesis among the older 
African population. Our findings do not provide supportive evidence for mediation; however, 
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 Figures and Tables 
Figure 3.1 Conceptual diagram of causal pathways between HIV continuum stage and CVD risk behaviors mediated by 
physiological and psychological symptoms 
 
Note: Absence of an arrow from HIV+ unaware to psychological symptoms indicates no hypothesized mediation via psychological 
symptoms. Dashed lines indicate that symptom pathways are attenuated among individuals who are HIV+ on treatment. Arrows 
between physiological and psychological symptoms are omitted as the relationships between mediators were not tested in this study 




Figure 3.2 Sample eligibility flowchart 
 
Note: Insufficient data to classify HIV continuum stage was primarily due to refusing consent to dried blood spot 
(DBS) testing (7%) or invalid DBS test data (3%) 
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Table 3.1 Sample characteristics, adults aged 40 years and older residing in rural 
Agincourt district, South Africa, enrolled in HAALSI study, 2014-2015 (n=4,061) 
 Male, n=1,858 Female, n=2,203 Total, n=4,061 
 n (%) n (%) n (%) 
Demographics    
Age group    
40-49 325 (17%) 442 (20%) 767 (19%) 
50-59 492 (26%) 685 (31%) 1,177 (29%) 
60-69 543 (29%) 556 (25%) 1,099 (27%) 
70+ 498 (27%) 520 (24%) 1,018 (25%) 
Completed primary education 424 (23%) 402 (18%) 826 (20%) 
Employed (full or part-time) 358 (19%) 311 (14%) 669 (16%) 
Married 1,289 (69%) 853 (39%) 2,142 (53%) 
Poorest 40%1 737 (40%) 886 (40%) 1,623 (40%) 
HIV-related    
HIV continuum stage    
HIV– 1,400 (75%) 1,638 (74%) 3,038 (75%) 
HIV+ unaware 112 (6%) 163 (7%) 275 (7%) 
HIV+ aware untreated 40 (2%) 53 (2%) 93 (2%) 
HIV+ on treatment 306 (16%) 349 (16%) 655 (16%) 
Virally suppressed (among HIV+) 231 (54%) 282 (53%) 513 (54%) 
CVD risk behaviors    
Tobacco smoking2 364 (20%) 7 (<1%) 371 (9%) 
Hazardous alcohol use3 290 (16%) 96 (4%) 386 (10%) 
Sedentary behavior4 774 (42%) 957 (43%) 1,731 (43%) 
CVD history    
Hypertension 650 (35%) 1,075 (49%) 1,725 (42%) 
Dyslipidemia or heart disease 218 (12%) 295 (13%) 513 (13%) 
Diabetes 118 (6%) 152 (7%) 270 (7%) 
Physiological symptoms    
Muscle weakness 1,554 (84%) 1,106 (50%) 2,660 (66%) 
Pain 131 (7%) 212 (10%) 343 (8%) 
Cognitive difficulties 
(memory/concentration/learning) 
737 (40%) 974 (44%) 1,711 (42%) 
Physical dysfunction (difficulties with ADLs) 175 (9%) 178 (8%) 353 (9%) 
Psychological symptoms    
Depressive symptoms (CESD-8 score 5+ out 
of 8) 
124 (7%) 194 (9%) 318 (8%) 
Low subjective well-being 528 (28%) 635 (29%) 1,163 (29%) 
Abbreviations: ADL - Activities of daily living; CESD - Center for Epidemiological Studies Depression Scale; 
HAALSI - Health and Aging in Africa: A Longitudinal Study of an INDEPTH Community in South Africa 
1 Based on household wealth index. 
2 Self-reported current use of smoking tobacco (cigarettes, cigars or pipes). 
3 AUDIT-C score >4 for men, >3 for women out of 7 total points. 




Table 3.2 Prevalence ratios (PRs) for CVD risk behavior by HIV continuum stage, overall and by sex 
 Tobacco smoking Hazardous alcohol use Sedentary behavior 
 Unadjusted 
PR (95% CI) 
Adjusted1 
PR (95% CI) 
Unadjusted 
PR (95% CI) 
Adjusted1 
PR (95% CI) 
Unadjusted 
PR (95% CI) 
Adjusted1 
PR (95% CI) 
Overall (n=4,061)       
HIV status       
HIV- reference reference reference reference reference reference 
HIV+ (all) 1.25 (1.00, 1.55) 1.15 (0.93, 1.43) 1.07 (0.86, 1.33) 1.01 (0.81, 1.25) 0.84 (0.77, 0.92) 0.87 (0.80, 0.95) 
HIV continuum stage       
HIV- reference reference reference reference reference reference 
HIV+ unaware 1.19 (0.82, 1.72) 1.07 (0.74, 1.56) 1.19 (0.84, 1.69) 1.09 (0.78, 1.54) 0.95 (0.82, 1.09) 0.99 (0.85, 1.14) 
HIV+ aware untreated 1.50 (0.87, 2.58) 1.40 (0.81, 2.39) 1.13 (0.63, 2.06) 1.11 (0.61, 1.99) 0.80 (0.60, 1.05) 0.83 (0.63, 1.09) 
HIV+ on treatment 1.24 (0.97, 1.60) 1.15 (0.90, 1.48) 0.92 (0.70, 1.20) 0.87 (0.66, 1.14) 0.79 (0.70, 0.88) 0.81 (0.73, 0.91) 
       
Males (n=1,858)       
HIV status       
HIV- reference reference reference reference reference reference 
HIV+ (all) 1.28 (1.05, 1.57) 1.21 (0.99, 1.49) 1.10 (0.86, 1.40) 1.05 (0.82, 1.33) 0.84 (0.77, 0.92) 0.89 (0.78, 1.02) 
HIV continuum stage       
HIV- reference reference reference reference reference reference 
HIV+ unaware 1.37 (0.90, 1.83) 1.24 (0.81, 1.67) 1.45 (0.92, 1.98) 1.31 (0.84, 1.77) 0.89 (0.67, 1.11) 0.94 (0.71, 1.16) 
HIV+ aware untreated 1.64 (0.84, 2.44) 1.55 (0.81, 2.30) 0.97 (0.24, 1.70) 0.94 (0.24, 1.64) 0.81 (0.47, 1.16) 0.84 (0.48, 1.20) 
HIV+ on treatment 1.22 (0.93, 1.50) 1.17 (0.90, 1.45) 0.91 (0.63, 1.19) 0.88 (0.62, 1.15) 0.86 (0.72, 0.99) 0.87 (0.73, 1.01) 
       
Females (n=2,203)2       
HIV status       
HIV- reference reference reference reference reference reference 
HIV+ (all) 1.26 (0.24, 6.47) 1.27 (0.27, 5.92) 1.04 (0.67, 1.65) 1.02 (0.65, 1.60) 0.82 (0.72, 0.92) 0.86 (0.75, 0.96) 
HIV continuum stage       
HIV- reference reference reference reference reference reference 
HIV+ unaware 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 0.84 (0.15, 1.52) 0.82 (0.16, 1.48) 0.98 (0.80, 1.15) 1.02 (0.84, 1.20) 
HIV+ aware untreated 0.00 (0.00, 0.00) 0.00 (0.00, 0.00) 1.72 (0.05, 3.38) 1.83 (0.13, 3.53) 0.78 (0.50, 1.07) 0.82 (0.52, 1.13) 
HIV+ on treatment 1.88 (0.37, 9.64) 1.96 (0.41, 9.32) 0.91 (0.40, 1.42) 0.88 (0.38, 1.38) 0.73 (0.61, 0.84) 0.76 (0.64, 0.88) 
1 Prevalence ratios were calculated using log-Poisson regression and robust standard errors, adjusted for age, education (at least primary), employed (full or 
part-time), wealth index (poorest 40% vs. richest 60%), hypertension, dyslipidemia, diabetes and prior CVD. Bolded estimates are significant at α<0.05. 








1 Predicted prevalences were estimated by log-Poisson regression models after adjustment for covariates. 
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Figure 3.4 Predicted prevalence1 of 3 CVD risk behaviors by HIV continuum stage and sex 
 




Table 3.3 Prevalence (95% CI) of hypothesized mediators by HIV continuum stage and by outcome 
 Physiological symptoms Psychological symptoms 




















HIV continuum stage       
HIV− 67% (66%, 69%) 9% (9%, 11%) 44% (42%, 46%) 9% (8%, 10%) 8% (7%, 9%) 28% (27%, 30%) 
HIV+ unaware 58% (52%, 64%) 7% (5%, 11%) 34% (29%, 40%) 7% (4%, 11%) 7% (4%, 11%) 26% (21%, 31%) 
HIV+ aware untreated 56% (46%, 66%) 4% (2%, 11%) 47% (37%, 57%) 9% (4%, 16%) 7% (3%, 14%) 31% (23%, 41%) 
HIV+ on treatment 61% (57%, 65%) 5% (4%, 7%) 37% (34%, 41%) 7% (5%, 9%) 7% (5%, 9%) 30% (27%, 34%) 
       
Smoking       
No 64% (62%, 65%) 9% (8%, 10%) 43% (42%, 45%) 9% (8%, 10%) 8% (7%, 9%) 29% (27%, 30%) 
Yes 85% (81%, 88%) 7% (5%, 10%) 31% (27%, 36%) 9% (6%, 12%) 5% (3%, 8%) 27% (23%, 32%) 
Hazardous alcohol use       
No 64% (63%, 66%) 9% (8%, 10%) 43% (41%, 44%) 9% (8%, 10%) 8% (7%, 9%) 28% (27%, 30%) 
Yes 77% (73%, 81%) 7% (4%, 9%) 39% (34%, 44%) 10% (7%, 13%) 6% (4%, 9%) 35% (30%, 39%) 
Sedentary behavior       
No 63% (61%, 65%) 6% (5%, 7%) 40% (38%, 42%) 6% (5%, 7%) 7% (6%, 8%) 27% (25%, 29%) 
Yes 69% (67%, 71%) 11% (10%, 13%) 45% (42%, 47%) 12% (11%, 14%) 9% (7%, 10%) 31% (29%, 33%) 





Table 3.4 Adjusted prevalence ratios (PRs) for CVD risk behavior by HIV continuum stage, controlling for individual 
mediators 
CVD risk behavior Total effect Direct effect, after controlling for 
  Physiological symptoms Psychological symptoms 








HIV continuum stage Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
Tobacco smoking        
HIV− reference reference reference reference reference reference reference 
HIV+ unaware 1.07 (0.67, 1.47) 1.14 (0.71, 1.56) 1.07 (0.67, 1.47) 1.07 (0.67, 1.47) 1.04 (0.65, 1.43) 1.07 (0.67, 1.47) 1.07 (0.67, 1.47) 
HIV+ aware untreated 1.40 (0.64, 2.15) 1.52 (0.72, 2.32) 1.39 (0.64, 2.14) 1.40 (0.64, 2.15) 1.42 (0.66, 2.19) 1.39 (0.63, 2.15) 1.40 (0.64, 2.16) 
HIV+ on treatment 1.15 (0.87, 1.44) 1.20 (0.90, 1.49) 1.15 (0.86, 1.44) 1.15 (0.87, 1.44) 1.13 (0.85, 1.42) 1.15 (0.86, 1.44) 1.16 (0.87, 1.45) 
        
Hazardous alcohol use        
HIV− reference reference reference reference reference reference reference 
HIV+ unaware 1.09 (0.72, 1.47) 1.13 (0.75, 1.52) 1.09 (0.72, 1.46) 1.09 (0.72, 1.47) 1.08 (0.71, 1.45) 1.09 (0.72, 1.47) 1.10 (0.72, 1.48) 
HIV+ aware untreated 1.11 (0.46, 1.76) 1.16 (0.48, 1.83) 1.09 (0.45, 1.73) 1.11 (0.46, 1.76) 1.11 (0.45, 1.77) 1.11 (0.46, 1.76) 1.10 (0.45, 1.75) 
HIV+ on treatment 0.87 (0.63, 1.10) 0.89 (0.65, 1.13) 0.86 (0.63, 1.10) 0.87 (0.63, 1.10) 0.86 (0.63, 1.09) 0.87 (0.63, 1.10) 0.86 (0.63, 1.09) 
        
Sedentary behavior        
HIV− reference reference reference reference reference reference reference 
HIV+ unaware 0.99 (0.85, 1.13) 1.00 (0.85, 1.14) 0.99 (0.85, 1.14) 1.00 (0.85, 1.14) 0.99 (0.85, 1.14) 0.99 (0.85, 1.13) 0.99 (0.85, 1.13) 
HIV+ aware untreated 0.83 (0.60, 1.06) 0.83 (0.60, 1.07) 0.84 (0.60, 1.07) 0.83 (0.60, 1.06) 0.82 (0.59, 1.05) 0.83 (0.60, 1.06) 0.82 (0.60, 1.05) 
HIV+ on treatment 0.81 (0.72, 0.90) 0.82 (0.73, 0.91) 0.82 (0.73, 0.92) 0.82 (0.73, 0.91) 0.82 (0.73, 0.91) 0.81 (0.72, 0.90) 0.81 (0.72, 0.90) 
        
1 Prevalence ratios were calculated using log-Poisson regression and robust standard errors, adjusted for age, education (at least primary), employed (full or part-time), married, 






Figure 3.5 Forest plot of prevalence ratios for CVD risk behaviors by HIV continuum 




Table 3.5 Comparison of complete case analysis and MI regression model results 
CVD risk behavior 





HIV continuum stage Adjusted PR3 (95% CI) Adjusted PR3 (95% CI) 
Tobacco smoking   
HIV− reference reference 
HIV+ unaware 1.07 (0.74, 1.56) 1.02 (0.71, 1.47) 
HIV+ aware untreated 1.40 (0.81, 2.39) 1.42 (0.81, 2.49) 
HIV+ on treatment 1.15 (0.90, 1.48) 1.12 (0.88, 1.43) 
   
Hazardous alcohol use   
HIV− reference reference 
HIV+ unaware 1.09 (0.78, 1.54) 1.03 (0.74, 1.44) 
HIV+ aware untreated 1.11 (0.61, 1.99) 1.24 (0.70, 2.20) 
HIV+ on treatment 0.87 (0.66, 1.14) 0.89 (0.69, 1.14) 
   
Sedentary behavior   
HIV− reference reference 
HIV+ unaware 0.99 (0.85, 1.14) 0.96 (0.85, 1.10) 
HIV+ aware untreated 0.83 (0.63, 1.09) 0.84 (0.64, 1.10) 
HIV+ on treatment 0.81 (0.73, 0.91) 0.82 (0.74, 0.91) 
   
1 Prevalence ratios were calculated using log-Poisson regression and robust standard 
errors, adjusted for adjusted for age, education (at least primary), employed (full or 
part-time), married, poorest 40%, hypertension, dyslipidemia, and diabetes.  
2 Missing data was imputed for all variables except HIV continuum stage using 






Table 3.6 Sensitivity analyses for alternate exposure definitions 
CVD risk behavior Main analysis1 Scenario 12 Scenario 2 Scenario 3 
HIV continuum stage 
Adjusted 
PR3 (95% CI) 
Adjusted 
PR3 (95% CI) 
Adjusted 
PR3 (95% CI) 
Adjusted 
PR3 (95% CI) 
Tobacco smoking     
HIV− reference reference reference reference 
HIV+ unaware 1.07 (0.74, 1.56) 0.93 (0.54, 1.60) 1.07 (0.74, 1.56) 1.07 (0.74, 1.56) 
HIV+ aware untreated 1.40 (0.81, 2.39) 1.30 (0.90, 1.89) 1.06 (0.46, 2.44) 1.40 (0.81, 2.39) 
HIV+ on treatment 1.15 (0.90, 1.48) 1.15 (0.90, 1.48) 1.19 (0.94, 1.52) 1.29 (0.89, 1.89) 
HIV+ virally suppressed    1.09 (0.80, 1.47) 
     
Hazardous alcohol use     
HIV− reference reference reference reference 
HIV+ unaware 1.09 (0.78, 1.54) 1.13 (0.72, 1.78) 1.09 (0.78, 1.54) 1.09 (0.78, 1.54) 
HIV+ aware untreated 1.11 (0.61, 1.99) 1.07 (0.73, 1.58) 0.81 (0.32, 2.07) 1.11 (0.61, 1.99) 
HIV+ on treatment 0.87 (0.66, 1.14) 0.87 (0.66, 1.13) 0.90 (0.70, 1.17) 0.79 (0.49, 1.26) 
HIV+ virally suppressed    0.90 (0.66, 1.24) 
     
Sedentary behavior     
HIV− reference reference reference reference 
HIV+ unaware 0.99 (0.85, 1.14) 0.99 (0.82, 1.19) 0.99 (0.86, 1.14) 0.99 (0.85, 1.14) 
HIV+ aware untreated 0.83 (0.63, 1.09) 0.92 (0.78, 1.09) 0.86 (0.59, 1.24) 0.83 (0.63, 1.09) 
HIV+ on treatment 0.81 (0.73, 0.91) 0.81 (0.73, 0.91) 0.81 (0.73, 0.91) 0.81 (0.67, 0.98) 
HIV+ virally suppressed    0.82 (0.72, 0.93) 
1 Base case results represent the main adjusted model among both males and females. 
2 In scenario 1, “unaware” individuals were re-classified as “aware” if they reported being previously tested for HIV, had their last HIV 
test done at least 6 months ago and had a detectable viral load. In scenario 2, individuals who tested ART-negative but reported 
being on ART were re-classified as ART-positive. In scenario 3, “treated” individuals who had an undetectable viral load test were 
re-classified into a separate “virally suppressed” group. 
3 Prevalence ratios were calculated using log-Poisson regression and robust standard errors, adjusted for adjusted for age, education (at 




 DOES PERCEIVED LIFE EXPECTANCY MODIFY THE EFFECTS OF 
HIV ON CVD RISK BEHAVIORS? A SELF-REGULATION HYPOTHESIS 
 Abstract 
Background: Cardiovascular disease (CVD) risk behaviors are highly prevalent among people 
living with HIV (PLWH). Evidence suggests that HIV itself may influence CVD risk behaviors, 
making them a particularly important CVD prevention target in this population. Modifying CVD 
risk behaviors, however, has proven difficult for PLWH; identifying drivers of unhealthy 
behaviors is therefore crucial for designing effective interventions. Self-regulation theory 
postulates that health behaviors depend on individuals’ beliefs about the health threats they 
expect to face in the future. Thus, perceived life expectancy (PLE) may be a relevant factor for 
health prevention behaviors, especially those that are related to age-related health conditions, 
such as CVD. We hypothesized that individuals with low PLE would be more prone to adopting 
unhealthy behaviors as a result of their HIV than those with high PLE. This study aimed to test 
the joint effects of HIV continuum stage and low PLE on CVD risk behaviors among older 
adults.  
Methods: We conducted secondary analyses of baseline data from a population-based cohort 
study of adults 40 years and older in rural Agincourt district in South Africa. HIV continuum 
stage was assessed using biomarker data on HIV infection status, detectable ARVs and self-
reported HIV status to construct four groups (HIV-negative, HIV-positive unaware, HIV-positive 
aware untreated, HIV-positive on treatment). Low PLE was defined as having <50% self-
reported probability of survival to old age (between 80 and 100 years depending on the current 
age of the participant). These data were combined to construct a composite variable of HIV 
continuum stage and PLE. Outcomes were self-reported current smoking, hazardous alcohol use 
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and sedentary behavior.. Log-Poisson regression models were fit to assess the prevalence ratios 
(PR) of each CVD risk behavior across joint categories of HIV continuum stage and low vs. high 
PLE to assess whether effects of HIV continuum stage on each CVD risk behavior varied by 
PLE level.  
Results: A total of n=3,232 participants were included in the study, among whom 10% were 
smokers, 10% were hazardous alcohol users and 41% were sedentary. Smoking was associated 
with HIV continuum stage only among those with low PLE. Compared to the HIV-negative and 
high PLE reference group, the highest prevalence of smoking was observed among the HIV-
positive aware untreated and low PLE group: PR (95% CI) = 4.43 (1.79, 10.97). In contrast, no 
significant effects of HIV continuum stage or low PLE were observed for hazardous alcohol use, 
and protective effects were observed for sedentary behaviors, with the lowest prevalence of 
sedentary being observed in the HIV-positive on treatment and low PLE group: 0.55 (0.37, 0.83). 
Findings were minimally sensitive to missing data on PLE. 
Discussion: The results of this study suggest that the effects of HIV continuum stage on smoking 
are stronger among individuals with low vs. high PLE. However, no such findings were noted 
with regards to hazardous alcohol use and sedentary behaviors. This study lends support to the 
self-regulation hypothesis for smoking in HIV-positive populations. Further research is 




People living with HIV (PLWH) experience higher rates of cardiovascular disease (CVD) than 
the general population.1-4 This excess risk is due in part to elevated behavioral risk factors, such 
as tobacco smoking, hazardous alcohol use and sedentary behaviors.5-19 As a result, behavioral 
modification interventions have increasingly been offered to PLWH. However, these 
interventions have been shown to be largely ineffective, with recent systematic reviews showing 
that the benefits of smoking and alcohol cessation interventions for PLWH dissipate within as 
little as 6 months after the end of the intervention.20, 21 Although most individuals, upon 
receiving their HIV diagnosis, report renewed interest in making healthy behavior changes, only 
one-third successfully reduce their smoking and/or alcohol use and up to 10% may increase such 
behaviors instead.22, 23 Qualitative evidence suggests that this is not due to lack of motivation. 
For example, focus groups among HIV-positive smokers found that participants often expressed 
the desire to quit smoking; however, many believed that they would die from their HIV infection 
before they suffered the consequences of smoking.24 That is, intentions to stop unhealthy 
behaviors may be outweighed by competing concerns regarding the ultimate negative impact of 
HIV infection and the immediate pleasure derived from the behaviors themselves.25, 26 These 
conflicting motivations can undermine efforts to improve health behaviors and potentially 
explain why behavior modification interventions have not proven effective for PLWH. 
This hypothesis is consistent with the self-regulation model of illness, which provides a 
theoretical basis for why individuals respond in various ways when confronting a health threat 
such as HIV infection. Self-regulation theory postulates that an individual’s health behaviors 
depend not only on the health threats they currently face, but also on those they expect to face in 
the future.27, 28 A key feature is that individuals make predictions about their future and regulate 
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or modify their current behaviors in accordance with these predictions.29 Therefore, perceived 
life expectancy (PLE), which captures an individual’s self-rated probability of survival to old age 
when aging-related diseases would be of greatest concern, may influence their current and near-
term CVD prevention behaviors. As per self-regulation theory, we hypothesize that individuals 
with low PLE would have lower incentive to avoid CVD risk behaviors if they do not believe 
that the negative consequences (i.e., CVD complications) will manifest during their lifetime. 
Concepts from self-regulation theory have been used previously to explain various health 
behaviors in diverse patient populations, such as why lung cancer patients continue smoking 
after their diagnosis30 and what factors contribute to treatment non-adherence among PLWH.31 
Though these studies did not explicitly describe PLE, they found that health behaviors were 
often worse among persons with greater symptom severity and poorer perceived prognosis (e.g., 
perceived likelihood of survival ).30-32 Further, HIV-positive persons commonly hold the 
misconception that HIV is a “death sentence”, a belief that often persists even among those on 
treatment.32 These observations suggest that PLE likely varies by HIV infection, awareness and 
treatment status. If low PLE does indeed modify the effects of HIV-positive status on CVD risk 
behaviors, then its modifying effect would also vary by infection, awareness and treatment status 
as well.33 Specifically, we hypothesized that persons who have low versus high PLE would be 
more likely to engage in increased CVD risk behaviors based on changes in their health status as 
a result of becoming HIV-infected. Similarly, those who have low PLE would be more likely to 
increase their CVD risk behaviors after becoming aware of their status due to already heightened 
fears of mortality (in the absence of treatment). Finally, those who have low PLE would be more 
likely to reduce their behaviors after initiating HIV treatment based on the extent to which their 
illness improves or is anticipated to improve. Therefore, comparing the relationship between 
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HIV continuum stages and CVD risk behavior across PLE levels can help to unpack this 
potential relationship. 
PLE is likely not static over the course of an individual’s life. Thus, it may be useful to 
operationalize the concept of PLE as comprising two components: time-varying state and stable 
personality trait.34 The state component captures how PLE changes in response to life 
circumstances, while the trait component captures the degree to which individuals have an innate 
tendency to be more optimistic or pessimistic about their own survival. The state-trait distinction 
highlights uncertainties regarding the temporal relationships between PLE and HIV; under this 
framework, HIV status would alter the state component but not the trait component. A 
conceptual diagram of the relationship between HIV continuum stage, low PLE and CVD risk 
behaviors is displayed in Figure 4.1. 
The effects of HIV and PLE on CVD risk behaviors are of particular interest for older persons 
living with HIV, since CVD is strongly associated with age.35 Furthermore, older individuals 
comprise a fast-growing segment of the HIV-positive population, due to longer survival of 
PLWH on antiretroviral treatment, as well as data that demonstrate that such older populations 
remain at high risk of HIV acquisition due to failure of HIV prevention services to focus on this 
group and lower condom use and HIV testing rates as compared to younger age groups.36-39 This 
trend is especially notable in the sub-Saharan African (SSA) region, which has the highest 
burden of HIV in the world, which has experienced a substantial scale-up of access to HIV 
treatment, and which is undergoing drastic urbanization accompanied by associated increases in 
sedentary behaviors and diets higher in processed foods.40, 41 Currently, most HIV research 
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focuses on adolescents and younger adults of reproductive age; thus further research on HIV and 
CVD risk behaviors in older adults in sub-Saharan Africa (SSA) is needed. 
To address these knowledge gaps, we explored the relationship between HIV and PLE and three 
CVD risk behaviors among a population-based cohort of adults aged 40 years and over in rural 
Agincourt district in South Africa. As secondary objectives, we examined whether findings were 
sensitive to alternative definitions of PLE that distinguish state and trait components in different 
ways. 
 Methods 
4.3.1. Data source 
This analysis used baseline data from the HAALSI study, a cohort study of adults 40 years and 
older in rural Agincourt district in South Africa. A sex-stratified random sample of 6,281 adults 
living in Agincourt district was selected from the Agincourt Health and Demographic 
Surveillance System (HDSS) and invited to participate in the study. From this sample, a total of 
5,059 individuals were enrolled in the baseline cohort. Participants completed a survey designed 
to gather detailed information on overall health and functioning, including several HIV- and 
CVD-related measures. Consenting participants also completed a physical examination and 
provided dried blood spot (DBS) samples for biomarker testing. Participants were eligible for 
this analysis if they had valid data on all variables used in the analysis as described below. 
Survey instruments were translated from English to the local Shangaan language and 
administered by trained fieldworkers using electronic tablets. Recruitment and baseline data 
collection occurred from 2014 to 2015. The HAALSI study received ethical approvals from 
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Harvard School of Public Health, University of Witwatersrand in South Africa, and the 
Mpumalanga Provincial Research and Ethics Committee. 
4.3.2. Measures 
We constructed a categorical variable for HIV continuum stage, using a combination of DBS 
data on HIV infection and ART use status (detectable 3TC or FTC), and self-reported HIV status 
to create four categories: HIV-, HIV-positive unaware, HIV-positive aware untreated, and HIV-
positive on treatment. 
Three CVD risk behavior outcomes were defined using self-reported data. Smoking was defined 
as current use of tobacco products, including cigarettes, cigars or pipes. Hazardous alcohol use 
was assessed using the Alcohol Use Disorders Identification Test (AUDIT-C), a validated 
screening tool that elicits self-reported data on alcohol use frequency, severity and binge 
drinking. Out of a total of 12 possible points, we classified hazardous alcohol use using validated 
cut-points for men (>4) and women (>3), respectively.42, 43 Sedentary behavior was assessed 
using the International Physical Activity Questionnaire (IPAQ). We categorized individuals who 
failed to meet criteria for minimum physical activity as having sedentary behaviors. See 
Appendix Tables 5.7 and 5.8 for detailed information on the survey questions used to 
operationalize hazardous alcohol use and sedentary behavior. 
PLE was assessed using the question: “What is the percent chance that you will live to be X or 
more”, where X was an age between 80-100 chosen by the interviewer to be at least 10 years 
greater than the participant’s current age (median 25 years). Responses ranged from 0-100%. In 
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the absence of validated thresholds for this measure, we dichotomized low versus high PLE 
using a 50% cut-point. 
Several demographic and health-related variables were considered potential confounders of the 
relationships between HIV continuum stage, PLE and CVD risk behaviors, including sex, age 
(continuous), employment status (full- or part-time employment vs. neither), education 
(completed at least primary education), poorest 40% (as measured by a composite wealth index, 
based on household assets). 
A set of measures of HIV-related symptoms were also included as predictors of PLE for 
sensitivity analyses (see below). Muscle weakness was measured via hand grip strength tests and 
defined using validated clinical thresholds.44 Pain was assessed using the Brief Pain Inventory 
(self-reported severity of pain experienced and degree to which pain interferes with life).45, 46 
Physical dysfunction was defined as having difficulties in performing any one of six activities of 
daily living using the validated Katz Index of Independence in ADLs. Cognitive impairment was 
defined as self-reported difficulties with memory, concentration and/or learning new tasks. 
4.3.3. Analysis 
Sample characteristics were described using proportions for categorical data and measures of 
central tendency for continuous data. To assess whether PLE modified the effect of HIV on CVD 
risk behaviors, we ran log-Poisson regression models with robust standard errors including 
indicator variables for each combination of HIV status and high vs. low PLE. Prevalence ratios 
(PR) and 95% confidence intervals (CIs) for each CVD risk behavior were calculated for each 
category compared to the HIV-negative and high PLE reference group. To explore whether 
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effect estimates varied further by awareness and treatment status, we ran additional models using 
HIV continuum stage, including indicator variables further stratified by HIV continuum stage. In 
both sets of models, we examined the PRs to assess the joint effects of both exposures, and 
compared whether associations for a given HIV continuum stage on each CVD risk behavior 
differed by PLE level, with respect to magnitude and/or direction of association or statistical 
significance .47, 48 Directed acyclic graphs (DAG) were constructed to identify potential 
confounders necessary for adjustment.49 
4.3.4. Sensitivity analyses 
Due to substantial missing data in the PLE variable (n=869, 22% of the available sample), we 
conducted a secondary analysis to assess potential selection bias. While most of these missing 
values resulted from “don’t know” responses, we hypothesized that individuals who do not 
report their PLE would have been more likely to smoke, drink or engage in sedentary behavior. 
We re-ran analyses assuming that all individuals with missing PLE in fact had low PLE and 
assessed how results changed.  
As another sensitivity analysis, we created an alternative measure to isolate the trait component 
of PLE. We first hypothesized factors that might influence the time-varying state component of 
PLE. Linear regression was used to model PLE as a function of all hypothesized predictors for 
which data were available, including demographic characteristics (sex, age, education, 
employment status, and household wealth), CVD history (previously diagnosed hypertension, 
dyslipidemia, and diabetes), and HIV-related symptoms (muscle weakness, pain, physical 
dysfunction, and cognitive impairment). The aim of this model was to control for all variables 
that could theortically influence a person’s self-reported PLE at the time of the survey, i.e., all 
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sources of variability in PLE other than intrinsic trait differences. Demographic characteristics 
capture variability by sex and age, which are known predictors of actual life expectancy, and 
socioeconomic status, which represent health-related resources such as nutrition and accessing 
care. Health characteristics such as CVD history and HIV-related symptoms capture known 
health issues that would likely influence one’s perceived future health trajectory and 
consequently their likelihood of survival. Other potential predictors of PLE were tested but did 
not substantially change model results and were thus not included for parsimony (data not 
shown). The resulting model is represented by the following equation:  
𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖 = 𝛽𝛽0𝑖𝑖 + ∑𝛽𝛽𝑖𝑖𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷ℎ𝑖𝑖𝑖𝑖𝑖𝑖 + ∑𝛽𝛽𝑖𝑖𝐻𝐻𝐷𝐷𝐷𝐷𝐻𝐻𝐻𝐻ℎ 𝑖𝑖ℎ𝐷𝐷𝐷𝐷𝐷𝐷𝑖𝑖𝐻𝐻𝐷𝐷𝐷𝐷𝑖𝑖𝑖𝑖𝐻𝐻𝑖𝑖𝑖𝑖𝑖𝑖 + 𝜀𝜀𝑖𝑖  
The resulting residual error term, εi, is the difference between an individual’s observed and 
predicted PLE: 𝜀𝜀𝑖𝑖 = 𝑃𝑃𝑃𝑃𝑃𝑃𝑖𝑖  − 𝑃𝑃𝑃𝑃𝑃𝑃� 𝑖𝑖. Linear regression implicitly treats this residual as a 
measurement of random or unexplained variability between the model’s predicted PLE and each 
individual’s observed PLE. Intuitively, it represents how different an individual’s response is 
compared to others with the same profile of demographic and health characteristics (Figure 4.2). 
As a sensitivity analysis, we assumed that these residuals were not due to random variability but 
rather that the variability in PLE not explained by predictors of the state component of PLE 
captures the trait component. Residuals were therefore interpreted as a measure of an 
individual’s intrinsic tendency to be more pessimistic or optimistic than others similar to them, 
under the strong assumption of no unmeasured predictors. Individuals with negative residuals 
were classified as having pessimistic traits, and those with positive residuals were classified as 
 
 99 
having optimistic traits.4 We re-ran the regression models using this alternative measure of PLE 
and examined whether findings were sensitive to this alternative measure. All analyses were 
performed using Stata v15.1 statistical software (College Station, Texas, USA). 
 Results 
4.4.1. Sample characteristics 
After excluding observations with any missing data, our final analytic sample included n=3,232 
participants, 64% of the entire cohort (Figure 4.3). The variables with the most missing data were 
PLE (23%) and HIV continuum stage (10%). Sample characteristics for the complete case 
sample are displayed in Table 4.1. Forty-seven percent were male, 49% were over age 60, and 
over 75% were poorly educated and unemployed. Overall, 837 (26%) were HIV-positive, of 
whom 225 (7%) were HIV+ unaware, 79 (2%) were HIV+ aware untreated and 533 (16%) were 
HIV-positive on treatment. The prevalence of current smoking, hazardous alcohol use and 
sedentary behaviors were 10%, 10% and 41%, respectively. The distribution of PLE was highly 
left-skewed, with a median of 80%. Only 473 (15%) participants were classified as having low 
(<50%) PLE as measured (Figure 4.4). 
                                                 
4 In contrast to Chapter 3, HIV-related symptoms here includes physiological symptoms and 
excludes psychological symptoms. We hypothesized that psychological measures such as 
depressive symptoms also comprise state and trait components and that their trait components 
would be highly correlated with the trait component of PLE. Therefore, controlling for 
depressive symptoms would control the PLE trait component the model is attempting to extract. 
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4.4.2. Regression models 
Results from regression models are reported in Table 4.2. PRs for all CVD risk behaviors were 
null for all high PLE and HIV-positive groups compared to the high PLE and HIV-negative 
reference group, indicating no main effects for HIV continuum stage. In contrast, PRs for the low 
PLE and HIV-negative group compared to the high PLE and HIV-negative group were 
significant for smoking (PR [95% CI]: 1.43 [1.03, 1.97]) and sedentary behavior (0.77 [0.67, 
0.89]); these findings suggest significant main effects of low PLE on elevated smoking and 
lower sedentary behaviors, and no main effects of PLE on hazardous alcohol use. Joint effects of 
HIV continuum stage and low PLE were stronger than low PLE alone for smoking and sedentary 
behavior. For these outcomes, joint effects varied across HIV continuum stage, with the highest 
smoking prevalence being observed among the HIV-positive aware untreated and low PLE 
group: adjusted PR (95% CI) = 3.09 (1.40, 6.83); however, differences between HIV continuum 
stages were not statistically significant (pairwise comparisons not shown). Hazardous alcohol use 
did not vary across categories of HIV continuum stage or PLE. In contrast, sedentary behaviors 
were lower among HIV-positive stage and low PLE groups relative to the HIV-negative and high 
PLE group, and did not vary by awareness or treatment status. These patterns are visually 
apparent in predicted prevalence charts displayed in Figure 4.5. 
Of note, when comparing all HIV-positive versus HIV-negative individuals, HIV-positive status 
was significantly associated with lower sedentary behaviors in unadjusted analyses: PR (95% CI) 
= 0.87 (0.79, 0.97), but this association did not remain after adjustment for confounders: 0.97 
(0.87, 1.08). HIV-positive status was not significantly associated with smoking or hazardous 
alcohol use in unadjusted or adjusted analyses. Low PLE alone, however, was associated with 
higher prevalence of smoking and lower prevalence of sedentary behaviors: adjusted PR (95% 
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CI) for smoking = 1.54 (1.13, 2.09), and for sedentary = 0.76 (0.65, 0.87). The joint effect of 
HIV-positive status and low PLE was stronger than low PLE alone for smoking: adjusted PR 
(95% CI) = 1.66 (1.10, 2.53), and sedentary behavior: 0.65 (0.47, 0. 91). 
4.4.3. Sensitivity analyses 
Trait component extraction. Results from the trait extraction model are reported in Table 4.3. 
The demographic characteristics, traditional CVD risk factors and physiological HIV symptoms 
collectively explained 7.5% of the total variability in PLE. The strongest predictors were 
physical dysfunction: coefficient (95% CI) = -6.4 (-9.5, -3.2), and education: 3.3 (1.1, 5.5). The 
distribution of residuals was left-skewed and ranged between -74.9 to 39.9 (Figure 4.4). Of the 
2,947 participants originally categorized as high PLE, n=884 (30%) were re-categorized as 
having a pessimistic PLE trait (Table 4.5). No participants were re-categorized in the opposite 
direction. 
Sensitivity analyses. Models re-run using alternative definitions of PLE are displayed in Tables 
4.6-4.8 for smoking, hazardous alcohol use, and sedentary behavior, respectively. In general, 
effects were attenuated in models where missing PLE values were re-classified as low PLE, due 
to CVD risk behaviors being less prevalent among the group with missing PLE than those who 
reported low PLE. 
In contrast, models using the PLE trait component, are more similar to those using the original 
PLE measure. Pessimistic personality trait (i.e., low PLE trait component) was associated with 
increased smoking, though this finding was only marginally significant at the p<0.10 level: 
adjusted PR (95% CI) = 1.27 (0.99, 1.63). Pessimistic personality trait was also significantly 
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associated with lower sedentary behaviors: PR (95% CI) = 0.82 (0.75, 0.91). Smoking was 
highest in the HIV-positive aware untreated and pessimistic trait group: PR (95% CI) = 2.65 
(1.49, 4.72). However, the significant effects found for the low PLE and HIV-negative and low 
PLE and HIV-positive on treatment groups in the original model were no longer significant in 
the PLE trait component model. Predicted prevalence estimates are displayed graphically in 
Figures 4.6-4.8. As in the main analyses, no clear patterns emerged for the optimistic trait group. 
 Discussion 
In this study, we explored the relationships between HIV continuum stage, PLE, and smoking, 
hazardous alcohol use and sedentary behaviors in a population-based sample of older adults in 
South Africa. This study built upon prior research that shows that HIV continuum stage and PLE 
are independent risk factors for unhealthy behavior engagement. Results indicated that self-
reported CVD risk behaviors were common in this setting. The high prevalence of CVD risk 
behaviors we observed was similar to estimates from previous studies in Southern Africa. For 
example, the first South Africa National Health and Nutrition Examination Survey (SA 
NHANES) estimated the national smoking prevalence to be 15%, and the South African National 
HIV, Incidence, Behaviour and Communication (SABSSM) 2008 survey estimated the national 
prevalence of hazardous alcohol use to be 9%.50, 51 Data from the Global Ageing and Adult 
Health (SAGE) survey in South Africa estimated sedentary behavior prevalence of 42% among 
adults 18 years or older, using the Global Physical Activity Questionnaire.52 
We tested the hypothesis that PLE played a modifying role on the relationship between HIV and 
unhealthy behavior engagement as predicted by self-regulation theory. To this end, we examined 
the joint effects of HIV continuum stage and PLE on each outcome. We found significant main 
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effects of low PLE on smoking (higher risk) and sedentary behaviors (lower risk) and non-
significant effects on hazardous alcohol use (higher risk). These findings provide evidence that 
low PLE may be an independent predictor of some CVD risk behaviors in this population, but 
evidence was inconsistent across outcomes. We did not find main effects of HIV-positive status 
on any of the three CVD risk behaviors. However, non-significant differences in smoking 
prevalence were found when stratified further by awareness and treatment status in the low PLE 
group. Specifically, smoking was 1.4 times as common among low PLE and HIV-negative 
individuals as compared to the high PLE and HIV-negative reference group; the highest 
prevalence was among the low PLE and HIV-positive aware untreated group, which had three-
fold higher smoking prevalence than the high PLE and HIV-negative group. No significant 
effects were observed across the HIV continuum among those with high PLE. Our findings differ 
from previous studies which suggest that HIV-positive status is associated with increased 
smoking and alcohol use,25, 53-55 while supporting the hypothesis that individuals who are HIV-
positive and believe they have low probability of survival are more likely to smoke. In other 
words, our findings are consistent with the hypothesis that individuals who are HIV-positive and 
have low PLE would have the highest prevalence of smoking, which would be expected if they 
were causal partners of smoking. No prior studies to our knowledge have assessed the 
relationship between PLE and CVD risk behaviors. 
Our findings suggested that low PLE is an independent predictor of smoking, which may explain 
why some individuals do not change smoking behaviors after HIV infection. However, the fact 
that findings were inconsistent across outcomes is cause for skepticism. We observed no 
significant main or interaction effects of low PLE on hazardous alcohol use, and found protective 
main and interaction effects of low PLE on sedentary behaviors. It may be possible that the 
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effects of low PLE vary across health behaviors, as smoking is more generally recognized as 
harmful than alcohol use or sedentary behaviors.56 However, we cannot rule out reverse 
causation or the possibility that the available self-reported measures failed to properly capture 
the underlying constructs, potentially inducing spurious findings. Of note, the protective effects 
observed for sedentary behavior run counter to our hypothesis. This likely reflects poor construct 
validity, as our measure of sedentary behavior included non-recreational physical activity, which 
would be associated with manual labor, characteristic of low socioeconomic status (SES) work. 
If HIV risk were higher among individuals with lower SES, this could explain the low 
prevalence of sedentary behaviors among all HIV-positive stage groups; the relationships 
between SES and HIV risk has proven to be complex, however.57 Furthermore, the high degree 
of missing data on PLE reflected a large number of “don’t know” responses, suggesting that 
participants may have had difficulty with comprehension or were unwilling to answer. Missing 
responses may have been more likely among individuals with low PLE and unhealthy behaviors, 
resulting in selection bias. Findings from our sensitivity analysis suggested that while results 
were attenuated, they were not very sensitive to missing data, and whether missing responses 
were truly more likely to be from individuals with low PLE remains speculation. 
Our study had several limitations. Due to small sample sizes, we were underpowered to detect 
small associations, particularly in the HIV-positive unaware group (n=79). Nonetheless, we 
observed strongest effects in the HIV-positive aware untreated and low PLE group for smoking, 
which we hypothesized a priori would be the most susceptible group. Perhaps more importantly, 
the cross-sectional nature of the data hindered our ability to identify the directional relationships 
between HIV continuum stage, PLE, and CVD risk behaviors. Studies of behavioral outcomes 
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are especially susceptible to this limitation as it is well-known in the psychological literature that 
there is high inter-individual variability in behavioral responses to health-related stress.29 
This concern partly motivated the trait component analysis. By isolating the trait component of 
PLE, we aimed to remove sources of variability that could have occurred after becoming 
infected, diagnosed or treated for HIV. Effect estimates held when using the trait component 
instead of PLE as measured, except in the models for smoking; nonetheless, while findings for 
smoking no longer remained significant, prevalence estimates followed similar patterns, 
suggesting that findings were not highly sensitive. However, little variability (7%) was 
collectively explained by the set of predictors included in the trait extraction model, and few 
participants were re-classified using the new measure overall. While it is theoretically possible 
that over 90% of the variability in PLE is truly determined by intrinsic personality traits, the 
absence of model specification errors is a strong and untestable assumption. Notably, we cannot 
rule out the existence of important unmeasured predictors of PLE, e.g., family health history, 
access to health care and social supports from family or caregivers. The use of linear regression 
was also likely an oversimplification of the relationship between PLE and its predictors. More 
importantly, existing research on the state-trait distinction utilizes repeated measures, 
hypothesizing that differences observed across time in the same individual capture state 
components and similarities across time capture trait components, the so-called latent state-trait 
approach.58 In the absence of repeated measures, we adapted this approach to cross-sectional 
data, which relied on the stronger assumption that different individuals would be comparable 
after controlling for other measured predictors of PLE. 
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Strengths of this study include the large population-based sample which ensured representation 
across the HIV care continuum, as opposed to clinic-based samples or external general 
population comparison groups typically employed by other studies. In addition, the restriction of 
the sample to older adults yielded novel findings in an under-studied population that is especially 
prone to CVD risk. The older age distribution of our sample also likely strengthened our ability 
to detect any effects of PLE. 
 Conclusion 
In conclusion, our study found that PLE was a strong independent predictor for smoking, but not 
for hazardous alcohol use or sedentary behaviors. Relationships between HIV continuum stage 
and CVD risk behaviors differed by PLE, with the strongest associations observed among the 
low PLE group. Our results suggest that screening and counseling for additional smoking 
cessation resources could be targeted towards persons with low PLE. However, further research, 
especially with prospective follow-up, is necessary to confirm these findings and unpack the 
reasons for lack of or opposite findings for hazardous alcohol use or sedentary behaviors, which 
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 Figures and Tables 
Figure 4.1 Conceptual diagram of relationship between HIV continuum stage, low 
perceived life expectancy (PLE) and CVD risk behaviors 
 
Note: Bolded line indicates stronger pathways among individuals who are HIV+ and aware of 
their status but untreated, while dashed line indicates attenuated pathway among individuals 
who are HIV+ on treatment. Red arrows indicate confounding pathways and blue arrows 
indicate effect modification pathways. 
Figure 4.2 Illustration of model for perceived life expectancy (PLE) and extraction of PLE 
trait component, εi 
 
Negative residuals represent individuals who believed they would die sooner than predicted 
based others with the same profile of demographic and health-related characteristics used to 
estimate the regression line. 
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Figure 4.3 Sample eligibility flowchart for effect modification analysis 
 
Note: Insufficient data to classify HIV continuum stage was primarily due to refusing consent to dried blood spot 





Table 4.1 Sample characteristics 
 Complete cases 
n=3,232 
Variable n (%) 
Demographics  
Male 1,523 (47%) 
Age group 1,523 (47%) 
40-49 661 (20%) 
50-59 972 (30%) 
60-69 873 (27%) 
70+ 726 (22%) 
Completed primary education 732 (23%) 
Employed (full or part-time) 585 (18%) 
Married 1,750 (54%) 
Poorest 40%1 1,265 (39%) 
HIV-related  
HIV continuum stage  
HIV– 2,395 (74%) 
HIV+ unaware 225 (7%) 
HIV+ aware untreated 79 (2%) 
HIV+ on treatment 533 (16%) 
Virally suppressed (among HIV+) 436 (54%) 
CVD risk behaviors  
Tobacco smoking2 309 (10%) 
Hazardous alcohol use3 317 (10%) 
Sedentary behavior4 1,340 (41%) 
CVD history  
Hypertension 1,323 (41%) 
Dyslipidemia or heart disease 415 (13%) 
Diabetes 219 (7%) 
Physiological symptoms5  
Muscle weakness 2,085 (65%) 
Pain 258 (8%) 
Cognitive difficulties (memory/concentration/learning) 1,353 (42%) 
Physical dysfunction (difficulties with ADLs) 240 (7%) 
Psychological symptoms  
Depressive symptoms (CESD-8 score 5+ out of 8) 221 (7%) 
Low subjective well-being 869 (27%) 
Low perceived life expectancy (<50%) 473 (15%) 
1 Based on household wealth index. 
2 Self-reported current use of smoking tobacco (cigarettes, cigars or pipes). 
3 AUDIT-C score >4 for men, >3 for women out of 7 total points. 
4 Does not meet criteria for minimal physical activity using IPAQ scoring. 
5 Physiological symptoms were included as determinants of perceived life 





Figure 4.4 Distribution of perceived life expectancy 
 
Note: X was an age between 80-100, chosen by the interviewer to be at least 10 years greater  




Table 4.2 Prevalence ratios (PRs) for 3 CVD risk behaviors across joint categories of HIV  continuum stage and perceived life 
expectancy (PLE) (n=3,232) 
 CVD risk behavior 
Model Tobacco smoking Hazardous alcohol use Sedentary behavior 
Parameter Unadjusted 
PR (95% CI) 
Adjusted 
PR1 (95% CI) 
Unadjusted 
PR (95% CI) 
Adjusted 
PR1 (95% CI) 
Unadjusted 
PR (95% CI) 
Adjusted 
PR1 (95% CI) 
HIV status       
High PLE / HIV− reference reference reference reference reference reference 
High PLE / HIV+ 1.26 (0.97, 1.63) 0.98 (0.75, 1.27) 1.12 (0.86, 1.46) 1.02 (0.78, 1.33) 0.87 (0.79, 0.97) 0.97 (0.87, 1.08) 
Low PLE / HIV− 1.38 (1.01, 1.90) 1.54 (1.13, 2.09) 1.34 (0.98, 1.82) 1.29 (0.95, 1.75) 0.81 (0.70, 0.93) 0.76 (0.65, 0.87) 
Low PLE / HIV+ 2.18 (1.43, 3.33) 1.66 (1.10, 2.53) 1.41 (0.85, 2.34) 1.32 (0.80, 2.16) 0.58 (0.42, 0.80) 0.65 (0.47, 0.91) 
       
HIV continuum stage       
High PLE / HIV− reference reference reference reference reference reference 
High PLE / HIV+ unaware 1.15 (0.73, 1.81) 0.86 (0.55, 1.34) 1.23 (0.81, 1.86) 1.07 (0.71, 1.61) 1.01 (0.85, 1.19) 1.13 (0.96, 1.33) 
High PLE / HIV+ aware untreated 1.33 (0.68, 2.60) 1.05 (0.54, 2.05) 1.23 (0.63, 2.39) 1.20 (0.63, 2.28) 0.92 (0.69, 1.22) 1.03 (0.79, 1.36) 
High PLE / HIV+ on treatment 1.21 (0.89, 1.65) 0.97 (0.71, 1.32) 0.97 (0.70, 1.35) 0.90 (0.65, 1.25) 0.81 (0.71, 0.93) 0.90 (0.79, 1.03) 
Low PLE / HIV− 1.28 (0.92, 1.79) 1.43 (1.03, 1.97) 1.37 (1.00, 1.86) 1.33 (0.98, 1.81) 0.83 (0.71, 0.96) 0.77 (0.67, 0.89) 
Low PLE / HIV+ unaware 2.36 (1.14, 4.91) 1.72 (0.84, 3.53) 1.09 (0.37, 3.21) 1.04 (0.37, 2.91) 0.60 (0.33, 1.09) 0.69 (0.38, 1.25) 
Low PLE / HIV+ aware untreated 4.43 (1.79, 10.97) 3.09 (1.40, 6.83) 1.36 (0.22, 8.55) 1.36 (0.23, 8.14) 0.56 (0.17, 1.88) 0.66 (0.21, 2.12) 
Low PLE / HIV+ on treatment 2.22 (1.40, 3.54) 1.81 (1.13, 2.86) 1.41 (0.80, 2.48) 1.26 (0.73, 2.20) 0.50 (0.34, 0.75) 0.55 (0.37, 0.83) 
       
1 Prevalence ratios were adjusted for age, education (at least primary), employed (full or part-time), wealth index (poorest 40% vs. richest 60%), hypertension, 
dyslipidemia, and diabetes. Bolded estimates are significant at α<0.05. 
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Figure 4.5 Predicted prevalence of 3 CVD risk behaviors by HIV continuum stage and PLE 
 
Model-predicted prevalences are adjusted for age, education (at least primary), employed (full or part-time), wealth 
index (poorest 40% vs. richest 60%), hypertension, dyslipidemia, and diabetes.
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Table 4.3 Regression model to extracting PLE trait component (residuals) 
Perceived life expectancy (%) Coefficient (95% CI) 
Demographics  
Male -0.80 (-2.56, 0.97) 
Age 0.03 (-0.05, 0.11) 
Completed primary education 3.31 (1.11, 5.50) 
Employed (full or part-time) -0.01 (-2.29, 2.26) 
Poorest 40% -0.61 (-2.33, 1.12) 
Traditional CVD risk factors  
Hypertension 0.53 (-1.22, 2.27) 
Dyslipidemia 0.85 (-1.59, 3.30) 
Diabetes -1.98 (-5.29, 1.33) 
Physiological HIV symptoms  
Weakness -1.54 (-3.48, 0.39) 
Pain 0.01 (-3.01, 3.02) 
Physical dysfunction -6.40 (-9.54, -3.25) 
Cognitive impairment -1.39 (-3.08, 0.31) 
Intercept 76.69 (71.59, 81.79) 





Figure 4.6 Distribution of residuals of perceived life expectancy (PLE) 
 
Note: vertical line denotes cut-point for classifying individual as pessimistic (<0) vs. optimistic 
(≥0) trait 
Table 4.4. Concordance between low perceived life expectancy (PLE) as measured and trait 
component 




 n (row %) n (row %) 
High PLE (> 50%) 2,063 (70%) 884 (30%) 
Low PLE (≤ 50%) 0 (0%) 509 (100%) 




Table 4.5 Sensitivity analyses for alternative PLE definitions: tobacco smoking 
 Tobacco smoking 
 PLE as measured 
(n=3,232) 
Re-classify missing 
PLE as low PLE 
(n=4,610) 
PLE trait component 
(n=3,232) 
 Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
HIV status    
High PLE / HIV− reference reference reference 
High PLE / HIV+ 0.98 (0.75, 1.27) 0.97 (0.75, 1.27) 0.96 (0.69, 1.33) 
Low PLE / HIV− 1.54 (1.13, 2.09) 1.28 (1.01, 1.62) 1.27 (0.99, 1.63) 
Low PLE / HIV+ 1.66 (1.10, 2.53) 1.05 (0.74, 1.49) 1.31 (0.95, 1.81) 
    
HIV continuum stage    
High PLE / HIV− reference reference reference 
High PLE / HIV+ unaware 0.86 (0.55, 1.34) 0.86 (0.55, 1.33) 0.93 (0.56, 1.56) 
High PLE / HIV+ aware untreated 1.05 (0.54, 2.05) 1.03 (0.53, 2.02) 0.56 (0.18, 1.74) 
High PLE / HIV+ on treatment 0.97 (0.71, 1.32) 0.97 (0.71, 1.32) 1.02 (0.70, 1.50) 
Low PLE / HIV− 1.43 (1.03, 1.97) 1.23 (0.97, 1.57) 1.25 (0.97, 1.61) 
Low PLE / HIV+ unaware 1.72 (0.84, 3.53) 1.02 (0.55, 1.88) 1.17 (0.66, 2.08) 
Low PLE / HIV+ aware untreated 3.09 (1.40, 6.83) 1.77 (0.81, 3.87) 2.65 (1.49, 4.72) 
Low PLE / HIV+ on treatment 1.81 (1.13, 2.86) 1.09 (0.73, 1.63) 1.23 (0.85, 1.79) 
    
1 Prevalence ratios were adjusted for age, education (at least primary), employed (full or part-time), wealth 







Table 4.6 Sensitivity analyses for alternative PLE definitions: hazardous alcohol use 
 Hazardous alcohol use 
 PLE as measured 
(n=3,232) 
Re-classify missing 
PLE as low PLE 
(n=4,610) 
PLE trait component 
(n=3,232) 
 Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
HIV status    
High PLE / HIV− reference reference reference 
High PLE / HIV+ 1.02 (0.78, 1.33) 1.02 (0.78, 1.32) 1.03 (0.75, 1.42) 
Low PLE / HIV− 1.29 (0.95, 1.75) 1.07 (0.85, 1.36) 1.11 (0.87, 1.42) 
Low PLE / HIV+ 1.32 (0.80, 2.16) 0.92 (0.63, 1.34) 1.05 (0.74, 1.50) 
    
HIV continuum stage    
High PLE / HIV− reference reference reference 
High PLE / HIV+ unaware 1.07 (0.71, 1.61) 1.07 (0.71, 1.61) 1.09 (0.67, 1.76) 
High PLE / HIV+ aware untreated 1.20 (0.63, 2.28) 1.19 (0.63, 2.27) 1.22 (0.58, 2.56) 
High PLE / HIV+ on treatment 0.90 (0.65, 1.25) 0.90 (0.65, 1.25) 0.91 (0.60, 1.36) 
Low PLE / HIV− 1.33 (0.98, 1.81) 1.09 (0.86, 1.37) 1.12 (0.88, 1.44) 
Low PLE / HIV+ unaware 1.04 (0.37, 2.91) 1.07 (0.58, 1.96) 1.04 (0.56, 1.94) 
Low PLE / HIV+ aware untreated 1.36 (0.23, 8.14) 0.94 (0.24, 3.63) 1.18 (0.42, 3.33) 
Low PLE / HIV+ on treatment 1.26 (0.73, 2.20) 0.77 (0.48, 1.24) 0.97 (0.64, 1.47) 
    
1 Prevalence ratios were adjusted for age, education (at least primary), employed (full or part-time), wealth 







Table 4.7 Sensitivity analyses for alternative PLE definitions: sedentary behavior 
 Sedentary behavior 
 PLE as measured 
(n=3,232) 
Re-classify missing 
PLE as low PLE 
(n=4,610) 
PLE trait component 
(n=3,232) 
 Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
Adjusted 
PR1 (95% CI) 
HIV status    
High PLE / HIV− reference reference reference 
High PLE / HIV+ 0.87 (0.79, 0.97) 0.99 (0.89, 1.10) 0.96 (0.84, 1.09) 
Low PLE / HIV− 0.81 (0.70, 0.93) 0.91 (0.84, 0.99) 0.82 (0.75, 0.91) 
Low PLE / HIV+ 0.58 (0.42, 0.80) 0.84 (0.71, 0.99) 0.79 (0.66, 0.93) 
    
HIV continuum stage    
High PLE / HIV− reference reference reference 
High PLE / HIV+ unaware 1.13 (0.96, 1.33) 1.15 (0.97, 1.36) 1.13 (0.94, 1.37) 
High PLE / HIV+ aware untreated 1.03 (0.79, 1.36) 1.06 (0.80, 1.39) 1.01 (0.73, 1.39) 
High PLE / HIV+ on treatment 0.90 (0.79, 1.03) 0.92 (0.80, 1.05) 0.85 (0.72, 0.99) 
Low PLE / HIV− 0.77 (0.67, 0.89) 0.92 (0.84, 0.99) 0.82 (0.74, 0.91) 
Low PLE / HIV+ unaware 0.69 (0.38, 1.25) 0.90 (0.68, 1.19) 0.85 (0.63, 1.15) 
Low PLE / HIV+ aware untreated 0.66 (0.21, 2.12) 0.44 (0.18, 1.06) 0.85 (0.52, 1.39) 
Low PLE / HIV+ on treatment 0.55 (0.37, 0.83) 0.81 (0.66, 0.99) 0.75 (0.61, 0.92) 
    
1 Prevalence ratios were adjusted for age, education (at least primary), employed (full or part-time), wealth 
index (poorest 40% vs. richest 60%), hypertension, dyslipidemia, and diabetes. Bolded estimates are 
significant at α<0.05. 
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Figure 4.7 Sensitivity analyses, predicted prevalence of smoking 
 
Note: scenario 1: PLE as measured, scenario 2: observations with missing PLE assumed to have low PLE, 




Figure 4.8 Sensitivity analyses, predicted prevalence of hazardous alcohol use 
  
Note: scenario 1: PLE as measured, scenario 2: observations with missing PLE assumed to have low PLE, 




Figure 4.9 Sensitivity analyses, predicted prevalence of sedentary behavior 
 
Note: scenario 1: PLE as measured, scenario 2: observations with missing PLE assumed to have low PLE, 






The overarching goal of this dissertation was to explore the causal relationship of HIV on CVD 
risk behaviors. This research question was motivated by qualitative evidence that people living 
with HIV (PLWH) often report adopting unhealthy behaviors as a means of coping with HIV-
related stress, and supported by established stress-coping theories in the psychological literature. 
To date, limited research attention had been devoted to CVD risk behaviors as an outcome of 
HIV overall, a gap which is especially notable for dietary and sedentary behaviors, and few of 
the available studies had quantitatively tested the stress-coping hypotheses previously 
mentioned. Furthermore, as per self-regulation theory, we hypothesized that perceived life 
expectancy (PLE) had a potential modifying role on the relationship between HIV and CVD risk 
behaviors. In addition, this study aimed to improve upon prior research in this area by 
contrasting the effects of HIV infection itself vs. the effects of awareness of one’s status and of 
being on treatment (i.e., using an HIV continuum approach). Evidence suggests different types of 
stress are experienced at each HIV continuum stage, yet existing studies use varied and often 
inadequate measures of HIV, resulting in imprecision in how study results are described and 
difficulties in synthesizing results across studies. This dissertation addressed these gaps via a 
systematic review of the literature and empirically using data from a population-based cohort of 
older adults in South Africa.  
 Summary 
In chapter 2, we systematically reviewed the available quantitative literature in support of an 
effect of HIV on CVD risk behaviors. Our review found that comparatively little research 
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attention had been placed on CVD risk behaviors as an outcome of, as opposed to a risk factor 
for HIV. Unsurprisingly, therefore, few longitudinal studies had been conducted on this topic, 
making concerns regarding temporality commonplace. Exposure measurement was also found to 
be highly variable and inconsistent across studies. In particular, the available measures were 
rarely equipped to differentiate effects across HIV continuum stages or were inadequately 
described. Few studies were conducted on dietary and sedentary behaviors among HIV-positive 
populations overall. Nonetheless, the available literature suggested that being HIV-positive was 
associated with higher risk of smoking and alcohol use. While some studies observed 
improvements in CVD risk behaviors immediately following receipt of a new diagnosis or 
initiation of HIV care, evidence suggested that these improvements were unlikely to be sustained 
long-term. 
In chapter 3, we used data from a population-based sample of adults aged 40 years and older in 
rural Agincourt district, South Africa, to explore patterns across the HIV continuum of three 
CVD risk behaviors, smoking, hazardous alcohol use and sedentary behaviors. As a secondary 
objective, we tested whether several proposed measures of physiological and/or psychological 
stress mediated the observed associations. We hypothesized a priori that CVD risk behaviors 
would be more prevalent among HIV-positive than HIV-negative individuals due to the physical 
toll of HIV symptoms; more prevalent among individuals who are aware vs. unaware of their 
status; and less prevalent among those on treatment due to the known salutary effects of 
antiretroviral drugs. We found that the prevalence of smoking, but not hazardous alcohol use nor 
sedentary behavior, were consistent with these patterns. However, due to low power, even the 
patterns of smoking were not statistically significant for all HIV continuum stage comparisons. 
Results differed by sex, in part due to low self-reported rates of smoking and hazardous alcohol 
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use among women. Lastly, our findings were not consistent with mediation hypotheses for any of 
the proposed mediators and thus did not support the stress-coping hypothesis. 
In chapter 4, we used data from the above-mentioned study to assess whether self-reported PLE 
modified the observed relationships. We hypothesized that individuals with low levels of PLE 
would assume that they would derive fewer benefits from CVD prevention and therefore be more 
likely to adopt unhealthy behaviors as a result of being HIV-positive. To test this hypothesis, we 
examined CVD risk behavior patterns across joint levels of HIV continuum stage and low vs. 
high PLE. Results from this analysis showed that low PLE was a strong independent predictor of 
smoking and that the patterns of smoking were stronger among individuals with low vs. high 
PLE. As in chapter 3, low power resulted in difficulties detecting significant findings that were 
consistent with our hypothesis, with the exception being for smoking. 
 Strengths and limitations 
This dissertation has several strengths. The systematic review from chapter 2 reiterated an 
important and often unstated knowledge gap regarding the evidence of differences in CVD risk 
behaviors by HIV status. Causal claims regarding the relationship between HIV and CVD risk 
behaviors remain commonplace, despite the inadequacy of the supporting data. To our 
knowledge, the analyses presented in Chapters 3 and 4 are the first to quantitatively test stress-
coping mechanisms that had been proposed based on prior qualitative research on CVD risk 
behaviors among PLWH. As a result, this dissertation tested novel mediation and effect 
modification analyses, supported firmly by established theory, and included a more 
comprehensive set of explanatory variables (i.e., physiological and psychological measures) than 
those considered in previous studies. Similarly, the analysis in Chapter 4 was the first to examine 
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the role of PLE on HIV-related outcomes. This dissertation was also the first to our knowledge to 
utilize the full HIV continuum to adequately distinguish between infection, awareness and 
treatment statuses. Though our findings did not support significant and consistent differences 
across stages, this approach could be used in future research to improve inference in HIV 
research. Lastly, the analyses in Chapters 3 and 4 were enhanced by strengths of the sample 
population: (1) population-representativeness, which mitigated important and widespread 
selection biases and generalizability issues in the clinic-based samples predominantly used in 
other studies; (2) restricted to older adults, a population of particular interest for aging-related 
health conditions; and (3) located in rural sub-Saharan Africa, an understudied region with 
respect to HIV comorbidities such as CVD. 
This dissertation also had several limitations. First, although the analytic methods aimed to 
address temporality issues via the HIV continuum approach, the cross-sectional nature of the 
data precludes establishment of temporality. Second, the main outcome measures were self-
reported which was likely to be subject to reporting bias that could have been differential by HIV 
continuum stage. Third, while we attempted to ground our hypotheses within established theory, 
the motivation for one’s healthy or unhealthy behaviors was not explicitly measured. Thus, the 
internal decision-making process underlying an individual’s observed behavior remains an area 
of speculation (indeed, it would remain so even if the behaviors themselves were not self-
reported). Fourth, we used a novel measure of PLE in Chapter 4, which raises questions 
regarding its construct validity. A key source of uncertainty is the extent to which PLE is itself 
influenced by HIV and other changes in health or life circumstances, the state-trait distinction 
explored in Chapter 4. We attempted to extract the trait component of PLE as a sensitivity 
 
 131 
analysis; however, the analytic approach was adapted from other methods that use repeated 
measures. Thus, it relied on stronger assumptions and was itself novel and unvalidated. 
 Implications for public health and future research 
As CVD prevention increasingly becomes a public health priority for HIV-positive populations, 
unhealthy lifestyle behaviors, which are prevalent and modifiable, represent potentially high-
yield targets for intervention. However, the limited success achieved to date suggests a need to 
better understand the underlying motivations for lifestyle behaviors. Understanding the influence 
of HIV itself on CVD risk behavior engagement and its mechanisms is crucial for identifying 
etiology and developing interventions. 
Findings from this dissertation did not follow the patterns of CVD risk behavior engagement by 
HIV continuum stage we hypothesized a priori, with the exception of elevated smoking among 
the HIV-positive aware untreated group. Findings also did not provide evidence in support of 
physiological or psychological stress-coping mechanisms as hypothesized. While it is possible 
that smoking is simply more likely to be adopted by HIV-positive individuals in the presence of 
stress, inconsistent findings across CVD risk behaviors prompts further research that may better 
test such hypotheses or uncover alternative explanations for null findings. However, it did reveal 
a potentially important role of PLE, where high levels of PLE may act as a buffer against the 
negative effects of HIV, particularly for smoking. This finding suggests that additional support to 
bolster optimism about one’s future, in complement with ART treatment initiation strategies, 
might enhance behavior modification for CVD prevention; future work will be required to 
empirically test such interventions. Finally, given the lifelong nature of HIV infection, further 
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studies should follow this example and use the continuum perspective that takes into account the 





Appendix Table 5.1 Search terms used in systematic literature review 
Pubmed/MEDLINE 
(smoking[Title/Abstract] OR tobacco[Title/Abstract] OR alcohol[Title/Abstract] OR 
diet[Title/Abstract] OR fruit[Title/Abstract] OR vegetable[Title/Abstract] OR 
nutrition[Title/Abstract] OR exercise[Title/Abstract] OR “physical activity”[Title/Abstract]) 
AND (incidence OR prevalence OR prevalent) AND (change OR difference OR modif* OR 
reduc* OR association) AND ("people living with HIV" OR "HIV-infected" OR "HIV-positive" 
OR "antiretroviral therapy" or "HIV diagnosis" or "HIV status") AND English[Language] AND 
("2000"[Date - Publication] : "3000"[Date - Publication]) 
Web of Science 
TS=((smoking OR tobacco OR alcohol OR diet OR fruit OR vegetable OR nutrition OR exercise 
OR "physical activity") AND (incidence OR prevalence OR prevalent) AND (change OR 
difference OR modif* OR reduc*) AND ("people living with HIV" OR "HIV-infected" OR 
"HIV-positive" OR "antiretroviral therapy" or "HIV diagnosis" or "HIV status")) AND 
PY=(2000-2018) 
Refined by: DOCUMENT TYPES: ( ARTICLE ) AND LANGUAGES: ( ENGLISH ) 
Timespan: 2000-2018. 
PsycINFO 
((smoking or tobacco or alcohol or diet or fruit or vegetable or nutrition or exercise or "physical 
activity") and (incidence or prevalence or prevalent) and (change or difference or modif* or 
reduc* or association) and ("people living with HIV" or "HIV-infected" or "HIV-positive" or 
"antiretroviral therapy" or "HIV diagnosis" or "HIV status")).mp. [mp=title, abstract, heading 
word, table of contents, key concepts, original title, tests & measures] 
limit to (english language and yr="2000 - 2017") 
EMBASE/MEDLINE 
(smoking OR tobacco OR alcohol OR diet OR fruit OR vegetable OR nutrition OR exercise OR 
'physical activity') AND (incidence OR prevalence OR prevalent) AND (change OR difference 
OR modif*) AND ('people living with hiv' OR 'hiv-infected' OR 'hiv-positive' OR "HIV 






Appendix Table 5.2 Cross-sectional analyses of smoking by HIV continuum stage 






stage measure(s) Comparison Results 
Covariates 
adjusted 
















VLS (blood test) VLS among smokers vs. non-smokers 
VLS by smoking: 
adjusted OR = 
0.48 (0.24, 0.93) 
age, race/ethnicity 















CD4 count category 
(<200 vs. 200-499 
vs. 500+) 
Smoking among CD4 
<200 vs. 200-499 vs. 
≥500 
prevalence = 41% 






country of birth, 
education, 
employment, 






Smoking among VLS 
vs. not VLS 
prevalence = 35% 
vs. 44% (Kruskal 
Wallis p<.001) 
ART use (medical 
records) 
Smoking among ART 
users vs. non-users 
38% vs. 45% 
(chi-sq p<.001) 
HIV+ vs. general 
population 
Smoking among HIV+ 
vs. general population 
prevalence = 
39.2% vs. 13%; 
adjusted PR = 3.0 
(p<.001) 














Length of HIV 
infection, 5-10 vs. 0-
5 years (medical 
records) 
Regular smoking 
among length of HIV 
infection 5-10 vs. 0-5 
yrs 
adjusted OR = 
1.46 (1.10, 1.94) 




duration of HIV 
infection 
CD4≤350 & 
VL≥1000 vs. other 
(medical records) 
Regular smoking 
among CD4≤350 & 
VL≥1000 vs. other† 
adjusted OR = 
0.81 (0.67, 0.98) 
ART duration 3-6 
vs. 0 yrs (medical 
records) 
Regular smoking 
among ART duration 
3-6years vs. 0 
adjusted OR = 
1.51 (1.04, 2.20) 
HIV+ vs. HIV- 
(general population) 
Regular smoking 
among HIV+ vs. HIV- 
prevalence = 79% 
vs. 34% (p<.001) 





(n=219) and not 













HIV+ ART+ vs. 
HIV+ ART- vs. 
HIV- controls) 
Smoking by HIV/ART 
status (ART+ vs. 
ART- vs. HIV-) 
prevalence = 













stage measure(s) Comparison Results 
Covariates 
adjusted 




in care (n=477) Clinic-based 
Cross-
sectional 
Smoking past 7 
days (exhaled 
CO) 
CDC stage of HIV 
infection (self-
report: acute HIV 
vs. latent HIV vs. 
AIDS) 
Smoking among HIV 
stage (acute vs. latent 
vs. AIDS) 
prevalence = 56% 
vs. 24% vs. 17% 
(chi-sq p=0.627) 





status ART status (self-report) 
Smoking among ART 
users vs. non-users 
adjusted OR = 




Ready to quit among 
ART users vs. non-
users 
adjusted OR = 
1.29 (0.50, 3.30) 











report: >= 20 











CD4 count among 
frequent vs. infrequent 
smokers 
mean difference = 
-25.5 (p=0.57) 
ART adherence, 
length of HIV 
diagnosis 
CD4 count among 
heavy/moderate vs. 
light smokers 
mean difference = 
-58.3 (p=0.12) 
Undetectable VL 
among frequent vs. 
infrequent smokers† 




vs. light smokers 
adjusted OR = 
0.43 (p<.001) 


























current vs. never 
smokers 
prevalence = 69% 
vs. 60% unadjusted 


















(biomarker) & ART 
use (medical 
records) 
Smoking among HIV- 
vs. HIV untreated vs. 
HIV treated 




9 Duval et al. (2008) France 
HIV+ patients 
in care (n=727) Clinic-based 
Cross-
sectional 





>500 vs. <200) 




prevalence = 47% 
vs. 38% 
(p=0.0583) 
age, sex, BMI, 
smoking, IDU, 
disclosure of HIV 











stage measure(s) Comparison Results 
Covariates 
adjusted 
10 Elf et al. (2017) 
Klerksdorp, 
South Africa 
HIV patients in 














adjusted OR = 




BMI, alcohol use 










HIV infection status 
(blood test) 
Smoking among HIV+ 
vs. HIV- 
adjusted OR = 0.0 
(0.0, 12.6) not stated 














HIV status (blood 
test or self-reported 
ART use) 
Smoking among HIV+ 
vs. HIV- 























Low CD4 count <50 
(medical records, 
prior to ART 
initiation) 
Regular smoking 
among high vs. low 
CD4† 
adjusted OR = 
0.67 (0.50, 0.91) 
country, sex, 
marital status, 









persons in rural 







Smoking, past 3 
days (self-
report) ART use, current 
(self-report) 
Current smoking 
among ART users vs. 
non-users 
adjusted OR = 
0.51 (0.17, 1.58) age, sex, ethnicity, marital status, 
education, 
drinking, drug use 
Heavy smoking, 
past 3 days 
(self-report) 
Heavy smoking among 
ART users vs. non-
users 
adjusted OR = 
1.56 (0.88, 2.76) 





















HIV status (blood 
test) 
Tobacco use among 
HIV+ vs. HIV- 
adjusted RR 
(men) = 1.46 
(1.30, 1.65); 
adjusted RR 
























HIV+ vs. HIV- 
(general population) 
Smoking prevalence 
among HIV+ vs. HIV- 
prevalence = 
















stage measure(s) Comparison Results 
Covariates 
adjusted 
(n=27731) Survey) Quit attempt, 
ever (self-
report) 
Quit rates among 
HIV+ vs. HIV- 
Lower quit rate 
among HIV+: no 
statistical test 
performed 


















Smoking among HIV+ 
vs. HIV-, by 10-year 
age band 
prevalence (20-
29) = 23% vs. 
35%; (30-39) 
49% vs. 41%; 
(40-49) 50% vs. 
39%; (50-59) 
27% vs. 41%; 
(60-69) 20% vs. 
24% 
unadjusted 








vs. prior vs. 
none) 
HIV status (blood 
test) 
Smoking among HIV+ 
vs. HIV- 
























Low VL <105 
copies/ml (blood 
test) 
Low VL among <10 
vs. 0 cigs/day; among 
>10 vs. 0 cigs/day† 
adjusted OR = 
0.50 (0.29, 0.87); 
adjusted OR = 
0.71 (0.38, 2.00) 
age, gender, body 
weight, alcohol, 
TB history, CD4, 
HIV 


















among HIV+ vs. HIV- 
prevalence = 






21 Shokoohi et al. (2018) Canada 











report: daily vs. 
frequent vs. 
none) 
HIV+ (blood test) 
vs. HIV- (general 
population) 
Current smoking 
among HIV+ vs. HIV- 
standardized 
prevalence = 
43.7% vs. 17.8%; 
difference = 
25.9% (22.9%, 
28.9%) age and ethnic group-standardized 
Daily smoking among 
HIV+ vs. HIV- 
prevalence = 













stage measure(s) Comparison Results 
Covariates 
adjusted 

















HIV+ (blood test) 
vs. HIV- (general 
population) 
Regular smoking 
among HIV+ vs. HIV- 
adjusted PRR 
(men) = 1.19 
(0.98, 1.45); 
adjusted PRR 


















missed dose past 
month [AACTG]) 
Current smoking 
among ART adherent 
vs. non-adherent† 
adjusted OR = 









CD4 (blood test: 
>350 vs. 200-350 
vs. <200 cells/ul) 
Current smoking 
among high vs. low 
CD4 
adjusted OR = 0.8 
(0.5, 1.2) 
VL detectable 




vs. detectable VL† 
adjusted OR = 
0.67 (0.53, 0.91) 
Note: * denotes studies that used cross-sectional data but the comparisons deemed relevant for this review were cross-sectional. 
† denotes relationships that were transformed from the original study publication to facilitate comparison in this review. 
Abbreviations: AACTG: Adult AIDS Clinical Trials Group, AIDS: Acquired Immune Deficiency Syndrome, ANC: Antenatal care, ART: Antiretroviral therapy, 
BMI: Body mass index, CO: Carbon monoxide, CVD: Cardiovascular disease, FSW: Female sex workers, HIV: Human immunodeficiency virus, IDU: Injection 
drug users, IeDEA: International Epidemiology Databases to Evaluate AIDS, MACS: Multicenter AIDS Cohort Study, MSM: Men who have sex with men, 
NHIS: National Health Interview Survey, OR: Odds ratio, PR: Prevalence ratio, RR: Risk ratio, SA NHANES: South Africa National Health and Nutrition 
Examination Survey, TB: Tuberculosis, VACS: Veterans Aging Cohort Study, VAS: Visual Analog Scale, VL: Viral load, VLS: Viral load suppression, WHO: 






Appendix Table 5.3 Cross-sectional analyses of alcohol use by HIV continuum stage 








stage measure(s) Comparison Results 
Covariates 
adjusted 











>95%, past 12 
months (self-report) 
>95% ART adherence 
among alcohol users vs. 
non-users 




















% ART adherence, 
past 3 months (self-
report) 
% ART adherence 
among absence vs. 
presence of alcohol 
dependence 

























VLS (blood test) VLS among hazardous alcohol use vs. others 
adjusted β = 0.34 
(p=.449) age, race/ethnicity 









Hazardous vs. no 
alcohol use, past 4 
weeks (self-
report) 
ART use vs. non-use 
(self-report) 
Hazardous alcohol use 
among ART users vs. 
non-users 




CD4 nadir >500 vs. 
<50 (self-report) 
Hazardous alcohol use 
among CD4 nadir >500 
vs. <50 
adjusted OR = 
2.65 (1.23-5.69) 
Care visits attended, 
past 6 months (self-
report) 
Hazardous alcohol use 
among >8 vs. <3 visits 
attended 
adjusted OR = 
0.45 (0.23-0.86) 














HIV status (blood 
test) 
Alcohol use among 
HIV+ vs. HIV- 
adjusted 
prevalence = 39% 


























ART adherent among 
non-drinkers vs. low vs. 
binge vs. heavy 
drinkers 
Prevalence = 80% 
(no alc) vs. 68% 
(low) vs. 58% 




















stage measure(s) Comparison Results 
Covariates 
adjusted 





















HIV status (blood 
test) 
HIV status among 
heavy vs. non-drinkers 
adjusted OR = 
1.51 (1.00, 2.28) 









substance use, past 
drinking, past 
alcohol treatment 




















≥5 [men] or ≥4 
women out of 12) 
VLS (blood test) 
Hazardous alcohol use 
by VLS vs. not VLS: 
adjusted OR = 0.95 
(0.81, 1.10) 
adjusted OR = 





hepatitis C virus, 
depression, drug 
use, clinical site 
CD4 ≥350 vs. <350 
(blood test) 
Hazardous alcohol use 
among CD4 ≥350 vs. 
<350 
adjusted OR = 
1.16 (0.99, 1.34) 










severity (4 levels), 
past year (self-
report; AUDIT-C) 
Length of HIV 
diagnosis (medical 
records) 
Alcohol use severity 
per year since HIV 
diagnosis 
adjusted PR = 1.00 
(0.97, 1.03) 
gender, skin color, 
education, income, 




ART use vs. non-use 
(medical records) 
Alcohol use severity by 
ART use vs. non-use 
adjusted PR = 1.57 
(0.79, 3.13) 









Heavy alcohol use 
(self-report: 5+ 
drinks at one time 
during the last 
month) 
ART adherent (self-
report: VAS and 
AACTG) 
Optimal adherence 
among heavy alcohol 
use vs. less† 
unadjusted OR = 
0.51 (0.35, 0.74) unadjusted 















past 6 mo) 
HIV status (blood 
test) 
Alcohol abstention 
among HIV+ vs. HIV- 
adjusted OR 
among IDUs = 
1.04 (0.72, 1.51); 
among non-IDUs 
= 0.58 (0.41, 0.81) 













stage measure(s) Comparison Results 
Covariates 
adjusted 










report: any vs. 
none) 
ART adherent, last 
30 days (self-report) 
Alcohol use among 
ART adherent vs. non-
adherent† 
adjusted OR = 
0.65 (0.42, 0.99) 
ART initiation, 
age, sex, CD4 at 
ART initiation, 
ART duration, 
ART side effects 

















HIV status (blood 
test) 
HIV+ status among 
alcohol users vs. non-
users 
adjusted OR = 
0.36 (0.04, 1.48) not stated 















ART adherent among 
alcohol use disorder vs. 
not AUD 
adjusted OR = 
























HIV-1 status (blood 
test) 
Alcohol abuse among 
HIV+ vs. HIV- 
prevalence = 48% 
vs. 36% ; χ2=1.89 
(NS) 
 



















HIV status (medical 
records: ICD-9) 
Alcohol abuse or 
dependence among 
HIV+ vs. HIV- status 
prevalence = 19% 
vs. 18%, t-test 
p<0.001 
race, ethnicity, sex 













No difficulties with 
ART adherence by 
alcohol use† 
adjusted OR = 


















stage measure(s) Comparison Results 
Covariates 
adjusted 




















Heavy alcohol use 
(self-report) 
HIV+ (blood test) 
vs. HIV- (general 
population) 
Heavy alcohol use 
among HIV+ vs. HIV- 
prevalence = 5.6% 
vs. 10.3%; 
ANOVA p<0.001 









drinking among HIV+ 
vs. HIV- 
prevalence = 
17.0% vs. 46.1%; 
ANOVA p<0.001 











report, AUDIT ≥8 
of 40) 
ART adherence 
≥95%, past 4 days 
(self-report: ACTG 
questionnaire) 
ART adherence among 
hazardous alcohol users 
vs. none† 
adjusted OR = 
0.21 (0.13, 0.38) 
country, sex, age, 
formal education, 
marital status, 






















AUDIT ≥8 of 40) 
Previously 
diagnosed out-of-
care vs. newly 




out-of-care (vs. HIV-) 
among non-harmful vs. 
harmful alcohol use 
adjusted RR = 




Newly diagnosed (vs. 
HIV-) among non-
harmful vs. harmful 
alcohol use 
adjusted RR = 
1.13 (0.58, 2.22) 










AUDIT ≥16 out 
of 20) 
HIV awareness 
(blood test and self-
report) 
Unaware of HIV 
infection among 
harmful vs. nonharmful 
drinking 
adjusted PR = 2.7 
(1.0, 7.6) 
duration in sex 
work (years), 
alcohol use prior 
to last vaginal sex 
with client and 
number of clients 
per week 












AUDIT ≥16 out 
of 20) 
ART users vs. non-
users (self-report) 
ART use among 
harmful vs. nonharmful 
alcohol use† 
adjusted PR = 0.53 
(0.26, 1.00) No. clients per 
week, housing, 
duration in sex 
work (years) VL suppression 
(blood test) 
VL suppression among 
harmful vs. nonharmful 
alcohol use† 
adjusted PR = 0.58 
(0.18, 2.00) 












report: missed any 
dose) 
ART adherence  among 
alcohol users vs. non-
users† 
adjusted OR = 
















stage measure(s) Comparison Results 
Covariates 
adjusted 












ART use among 
drinkers vs. non-
drinkers† 
adjusted OR = 
0.44 (0.25, 0.77) 
























AUDIT ≥8 of 40) 
Time since 
diagnosis, <1 year 
vs. ≥3 years (self-
report) 
Harmful drinking 
among <1 year vs. ≥3 
years since diagnosis 
adjusted OR = 




health, HIV risk 
behaviors ARV use (self-report) 
Harmful drinking 
among ARV users vs. 
non-users† 
adjusted OR = 
0.73 (0.60, 0.88) 











report: daily vs. 
none) 
HIV status (blood 
test) 
HIV+ status among 
daily alcohol users vs. 
non-drinkers 
adjusted OR = 



















Daily alcohol use 
(self-report) 
HIV status (blood 
test) 
Daily alcohol use 
among HIV+ vs. HIV- 
prevalence = 
30.2% vs. 18.0% unadjusted 













Lost to HIV care vs. 
engaged in care 
(self-report) 
Engaged in HIV care 
among alcohol users vs. 
non-users† 
prevalence = 32%; 
vs. 62%; adjusted 
OR = 0.36 (0.29, 
0.46) 
age, gender, race, 
sexual orientation, 
marital status, 
education, route of 
transmission 









drinks per week 
(self-report) 
HIV status (blood 
test) 
Drinks per week among 
HIV+ vs. HIV- 
median drinks per 





















past 30 days (self-
report: binge vs. 
none) 
High VL (blood test: 
>105 vs. ≤105 
copies/ml) 
High VL among binge 
vs. non-drinkers 
adjusted OR = 
0.66 (0.29, 1.50) 
age, gender, body 
weight, alcohol, 













stage measure(s) Comparison Results 
Covariates 
adjusted 















HIV status (blood 
test) 
HIV+ among current 
vs. non-drinker 
adjusted RR = 
0.53 (0.35, 0.81); 
in low SES 
stratum: adjusted 
RR = 2.37 (1.34, 
4.18) 
age, sex 











Alcohol use, past 
4 weeks (self-




Analog Scale [7 day 
recall] & AACTG 
measure [4 day 
recall]) 





measure) = 0.43 
(0.26, 0.71); 
adjusted OR (VAS 
measure) = 0.49 
(0.31, 0.79) 
age, time on 
ARVs, desire to 













use, past 12 
months (self-
report) 
Viral load <50 vs. 
≥50 copies/ml 
(blood test) 
VL undetectable among 
excessive alcohol users 
vs. others 



















Alcohol use times 
per week (self-
report: 0 vs. 1-2 
vs. 3+) 
HIV infection status 
(blood test) 
HIV+ status among 1-2 
vs. 0 alcohol use 
times/wk 
adjusted OR (1-2 
vs. 0) = 0.67 (0.55, 
0.82); adjusted OR 





























Alcohol use among 
HIV+ vs. HIV- 
prevalence = 73% 
vs. 76% (p=0.034) 
sex, age, ethnicity, 
education Drinking days, 
past month (self-
report) 
Drinking days among 
HIV+ vs. HIV- 
mediated via perceived 
stress 
 unstandardized 
coefficient = 0.68 
(p<0.05) 


















Drinking among HIV+ 
vs. HIV- 
prevalence = 














stage measure(s) Comparison Results 
Covariates 
adjusted 









report: AUDIT >8 





Hazardous alcohol use 
among HIV+ vs. 
general population 
prevalence 68% 
vs. 46%; adjusted 
OR = 1.9 (1.1, 3.4) 
sex, age 










Alcohol use past 
month (self-
report) HIV status (self-
report: lifetime 
diagnosis) 
Alcohol use among 
HIV+ vs. HIV- 
prevalence = 










among HIV+ vs. HIV- 
prevalence = 6.1% 
vs. 3.4%; p=0.018 













report: none vs. 
<1 drink/wk, 2-3, 





Alcohol among HIV+ 
vs. HIV- 
prevalence = 




age and ethnic 
group-
standardized 

















unhealthy vs. low 
risk (clinical 
records and self-
report: AUDIT >5 
[women] or >7 
[men] out of 12) 
HIV infection status 
(clinical records, 
blood test) 
HIV+ among unhealthy 
vs. low risk drinkers 
prevalence = 
52.1% vs. 55.9%; 
chi-squared p-
value = 0.081 
unadjusted 
>90% ART 
adherence, past year 
(clinical records) 
ART adherent among 
unhealthy vs. low risk 
drinkers 
prevalence = 
19.2% vs. 23.0%; 
chi-squared p-
value = 0.13 
CD4 count (blood 
test) 
CD4 count among 
unhealthy vs. low risk 
drinkers 
mean (SD) = 419 
(271) vs. 414 
(269); p-value = 
0.585 
log(VL) (blood test) 
log(VL) among 
unhealthy vs. low risk 
drinkers 
mean (SD) = 3.1 
(1.3) vs. 3.1 (1.3); 
p-value = 0.889 









>4 [men] or >3 






HIV vs. AIDS) 
HIV stage among AUD 
vs. no AUD 
prevalence 
symptomatic HIV 
= 45.7% vs. 
51.8%; prevalence 
AIDS = 42.2% vs. 









ART use among AUD 
vs. no AUD 
prevalence = 
85.0% vs. 90.4%; 












stage measure(s) Comparison Results 
Covariates 
adjusted 
Length of HIV 
infection (self-
report) 
Length of HIV 
infection among AUD 
vs. no AUD 
mean years = 5.4 
vs. 5.4; p-value = 
0.41 














report: AUDIT 8+ 
out of 40) 
HIV awareness 
(blood test and self-
reported prior 
awareness) 
Aware of HIV infection 
among AUD vs. no 
AUD† 
adjusted OR = 
0.47 (0.22, 0.99) 
covariates not 
stated 












report: AUDIT >7 
[men] or >8 





Hazardous alcohol use 
among ART adherent 
vs. non-adherent 
adjusted OR = 
0.53 (0.41, 0.69) 













Hazardous alcohol use 
among undetectable vs. 
detectable VL† 
unadjusted OR = 
0.61 (0.44, 0.84) 








alcohol use, past 6 
months (self-
report: AUDIT-C 
>3 out of 12) 
HIV clinical stage 
(clinical records: 
WHO stage III/IV 
vs. I/II) † 
Hazardous alcohol use 
among HIV stage I/II 
vs. III/IV 
unadjusted PR 
(men) = 0.72 
(0.48, 1.08); 





Hazardous alcohol use 
among ART users vs. 
non-users† 
adjusted PR (men) 
= 0.60 (0.37, 
0.98); (women) = 
0.56 (0.34, 0.91) 
religion, ART use, 
ART adherence, 
depression 












appointment and pill 
counts) 
ART adherence among 
alcohol users vs. non-
users 
prevalence = 
60.3% vs. 83.9%; 
adjusted OR = 













Appendix Table 5.4 Cross-sectional analyses of dietary behavior by HIV continuum stage 












Appendix Table 5.5 Cross-sectional analyses of sedentary behavior by HIV continuum stage 







stage measure(s) Comparison Results 
Covariates 
adjusted 
1 Allen et al. (2011) Caribbean 
HIV+ recipients 






past 12 months 
(self-report) 
>95% ART 
adherence, past 12 
months (self-report) 
No participation in  
exercise program 
among ART adherent 
vs. non-adherent† 




ART side effects 















HIV status (blood 
test or self-reported 
ARV use) 
Physical inactivity 
among HIV+ vs. HIV- 


















HIV status (blood 
test) 
Exercise level among 
HIV+ vs. HIV- 

















diagnosis, >3 vs. 1-3 
yrs (self-report) 
Physical inactivity 
among >3 vs. 1-3 yrs 
since diagnosis 











among ART users vs. 
non-users 
adjusted PR = 1.11 
(0.83, 1.48) 












No sports activity 
among HIV+ vs. HIV-
† 
prevalence = 38.7% 
vs. 25.8%; Mann-
Whitney p-value = 










Appendix Table 5.6 Summary of systematic review findings 
 CVD risk behavior 
 Smoking Alcohol use Poor diet Sedentary 
HIV continuum stage     
HIV infection + (n=15) M (n=22) No studies 0 (n=2) 
HIV awareness + (n=5) M (n=8) No studies + (n=2) 
HIV treatment M (n=10) − (n=27) No studies - (n=2) 
HIV immune/viral recovery − (n=9) − (n=15) 0 (n=1) No studies 
Note: This table summarizes the findings of the systematic review for each CVD risk 
behavior by HIV continuum stage comparison. Effect estimates were harmonized across 
studies to enable comparisons (i.e., associations were reversed if variables were reverse-coded 
in a given study). Symbols denote predominant direction of association observed for all 
studies included in each cell: + = predominantly positive; − = predominantly negative; 0 = 




Appendix Table 5.7 AUDIT-C questionnaire for hazardous alcohol use 
The table below contains a side-by-side comparison of alcohol use questions from the original 3-item AUDIT-C 
questionnaire and corresponding questions from the HAALSI study that will be used to approximate the AUDIT-C 
score. Points for each response option are in parentheses, and scoring method follows the table. 
 
Original AUDIT-C questions Corresponding HAALSI survey questions 
 0. Do you currently (or in the last 30 days) consume any 
alcoholic drinks such as beer, wine, spirits, fermented 
cider, thothotho or traditional beer? 
 a. Yes (proceed to next question) 
 b. No (0 pts, skip to question 3) 
1. How often do you have a drink containing alcohol? 
 a. Never (0 pts) 
 b. Monthly or less (1 pt) 
 c. 2-4 times a month (2 pts) 
 d. 2-3 times a week (3 pts) 
 e. 4 or more times a week (4 pts) 
1. How often do you have at least one alcohol drink? 
 a. Less than once per month (1 pt) 
 b. 1-3 days per month (2 pts) 
 c. 1-4 days per week (3 pts) 
 d. 5-6 days per week (4 pts) 
 e. Daily (4 pts) 
2. How many standard drinks containing alcohol do you 
have on a typical day? 
 a. 1 or 2 (0 pts) 
 b. 3 or 4 (1 pt) 
 c. 5 or 6 (2 pts) 
 d. 7 to 9 (3 pts) 
 e. 10 or more (4 pts) 
2. On days you drink, how many alcoholic drinks do you 
have? 
 a. Less than 1 (0 pts) 
 b. 1-2 (0 pts) 
 c. 3-4 (1 pt) 
 d. 5 or more (2 pts) 
3. How often do you have six or more drinks on a single 
occasion? 
 a. Never (0 pts) 
 b. Less than monthly (1 pt) 
 c. Monthly (2 pts) 
 d. Weekly (3 pts) 
 e. Daily or almost daily (4 pts) 
3. In the past year, did you ever take 6 or more drinks in 
a single morning, afternoon or night? 
 a. Yes (1 pt) 
 b. No (0 pts) 
 
Scoring: Total score is calculated as the sum of points for all questions (out of 12 maximum points for original 
AUDIT-C, or 7 maximum points for HAALSI). As in the original AUDIT-C, hazardous alcohol consumption is 
defined as 4 or more points for men and 3 or more for women (see Bush et al., 1998). In order to approximate the 
AUDIT-C using the HAALSI baseline questionnaire, the questions most closely resembling those in the original 
were chosen. Since the range of responses for HAALSI questions 2 & 3 reflect a lower maximum severity of alcohol 
use, hazardous alcohol consumption may be underestimated among the most heavy drinkers, those who typically 




Appendix Table 5.8 IPAQ scoring for physical activity 
 
Please consider your activity during a usual week. Think first about the time you spend doing work. Think of work 
as the things that you have to do such as paid or unpaid work, study/training, household chores, harvesting 
food/crops, fishing or hunting for food, seeking employment. In the following questions 'vigorous-intensity 
activities' are activities that require hard physical effort and cause large increases in breathing or heart rate, 
'moderate-intensity activities' are activities that require moderate physical effort and cause small increases in 
breathing or heart rate. 
1. Does your work involve mostly sitting or standing still, or walking for very short periods (less than 10 
minutes)? 
 a. Yes (skip to question 4a) 
 b. No (proceed) 
2a. Does your work involve vigorous activities (heavy lifting, digging, manual labour or construction) for at least 
10 minutes at a time? 
 a. Yes (proceed) 
 b. No (skip to question 3a) 
2b. In a usual week, how many days are spent doing vigorous activities as part of your work? On a usual day of 
vigorous work, how many hours are spent doing these activities? 
 ___ Days ___ Hours ___ Minutes 
3a. Does your work involve moderate-intensity activities (brisk walking or carrying light loads) for at least 10 
minutes at a time? 
 a. Yes (proceed) 
 b. No (skip to question 4a) 
3b. In a usual week, how many days are spent doing moderate-intensity activities as part of your work? On a 
usual work day, how many hours are spent doing moderate-intensity activities? 
 ___ Days ___ Hours ___ Minutes 
 
Please consider your activity during a usual week. These questions exclude the physical activities at work that you 
have already mentioned. These questions are about the usual way you travel to and from places. For example to 
work, for shopping, to market, to place of worship.  
4a. Do you walk or use a bicycle (for at least 10 minutes at a time) to get to and from places? 
 a. Yes (proceed) 
 b. No (skip to question 5) 
4b. In a usual week, how many days do you walk or cycle for at least 10 minutes to get to and from places? On a 
usual day, how many hours do you spend walking or cycling for travel? 
 ___ Days ___ Hours ___ Minutes 
 Please consider your activity during a usual week. The next questions, exclude the work and transport 
activities that you have already mentioned, they are about sports, fitness and recreational activities (leisure).  
5. In your spare time, do you engage in any vigorous or moderate-intensity physical activities lasting more than 
10 minutes at a time? 
 a. Yes (end) 
 b. No (proceed) 
6a. In your spare time do you do any vigorous activities like running, strenuous sport or exercise for at least 10 
minutes at a time? 
 a. Yes (proceed) 
 b. No (skip to question 7a) 
6b. In a usual week, how many days do you engage in vigorous activities as part of your leisure time? In a normal 
day, how many leisure hours are spent doing vigorous activities? 
 ___ Days ___ Hours ___ Minutes 
7a. In your spare time, do you engage in any moderately intense physical activities like walking or swimming for 
at least 10 minutes at a time? 
 a. Yes (end) 
 b. No (proceed) 
7b. In a normal week, how many days are spent engaging in moderately intense physical activity as part of your 
leisure time? How many leisure hours are spent doing moderate-intensity activities in a normal day?  




Scoring: Guidelines for using the International Physical Activity Questionnaire (IPAQ) define three categories of 
physical activity, which signify ‘total physical activity level’ inclusive of recreational as well as daily living and 
work-related activity (see Lee et al., 2011), as opposed to recreational only. This measure has have been validated in 
sub-Saharan African settings (see Oyeyemi et al., 2014): 
Insufficiently active (Category 1) 
Individuals who do not meet criteria for Categories 2 or 3 
Minimally active (Category 2) 
Individuals who meet any one of the following criteria but do not meet criteria for Category 3: 
a) 3 or more days of vigorous activity of at least 20 minutes per day OR 
b) 5 or more days of moderate-intensity activity or walking of at least 30 minutes per day OR 
c) 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities 
achieving a minimum of at least 600 MET-min/week 
Health-enhancing physical activity (HEPA) (Category 3) 
Individuals who meet any one of the following criteria: 
a) vigorous-intensity activity on at least 3 days achieving a minimum of at least 1500 MET-minutes/week 
OR 
b) 7 or more days of any combination of walking, moderate-intensity or vigorous intensity activities 
achieving a minimum of at least 3000 MET-minutes/week 
 
Total MET-minutes/week (φ) is calculated using the following formula: 
𝜑𝜑 = (3.3 𝑀𝑀𝑃𝑃𝑀𝑀𝑖𝑖 ×  𝑑𝑑𝐷𝐷𝑑𝑑𝑖𝑖𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤  ×  𝐷𝐷𝑖𝑖𝑚𝑚𝑤𝑤𝑤𝑤𝑤𝑤𝑤𝑤) + (4.0 𝑀𝑀𝑃𝑃𝑀𝑀𝑖𝑖 ×  𝑑𝑑𝐷𝐷𝑑𝑑𝑖𝑖𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑤𝑤𝑚𝑚𝑚𝑚  ×  𝐷𝐷𝑖𝑖𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑤𝑤𝑚𝑚𝑚𝑚)





Appendix Table 5.9 Measures of physiological and psychological HIV-related stress 
Survey 
question  
Question text Response options 
CD Depressive symptoms (CESD-8)  
 Now think about the past week and the feelings you have experienced. Please tell me if each of the 
following was true for you much of the time this past week. Would you say yes or no? 
 
CD001 Much of the time in the past week, you felt depressed Yes/No 
CD002 Much of the time in the past week, you felt that everything you did was an effort. Yes/No 
CD003 Much of the time in the past week, your sleep was restless. Yes/No 
CD004 Much of the time in the past week, you were happy. Yes/No 
CD005 Much of the time in the past week, you felt lonely. Yes/No 
CD006 Much of the time in the past week, you did not enjoy life. Yes/No 
CD007 Much of the time in the past week, you felt sad. Yes/No 
CD008 Much of the time in the past week, you could not get "going". Yes/No 
SW Subjective well-being (from Gallup World Poll)   
SW001 (Life satisfaction) All things considered, how satisfied are you with your life as a whole these days? Use a 
0 to 10 scale, where is 0 is dissatisfied and 10 is satisfied. 
Numeric (0-10) 
SW013 (Global life evaluation) Please imagine a ladder with steps numbered from 0 at the bottom to 10 at the 
top. Suppose we say that the top of the ladder represents the best possible life for you and the bottom of 
the ladder represents the worst possible life for you. On which step of the ladder would you say you 
personally feel you stand at this time, assuming that the higher the step the better you feel about your life, 
and the lower the step the worse you feel about it? Which step comes closest to the way you feel? 
Numeric (0-10) 
PT Performance tests (Hand grip strength test)  
PT043 Grip strength first LEFT Numeric (0-50 kg) 
PT044 Grip strength second LEFT Numeric (0-50 kg) 
PT045 Grip strength first RIGHT Numeric (0-50 kg) 
PT046 Grip strength second RIGHT Numeric (0-50 kg) 
PN Pain (Brief Pain Inventory)  
 (Pain severity) On a scale of 0 to 10, where 0 is “No pain” and 10 is “Pain as bad as you can imagine”, 
please rate your pain… 
 
PN003 … at its worst in the last 24 hours. Numeric (0-10) 
PN004 … at its least in the last 24 hours. Numeric (0-10) 
PN005 … on average. Numeric (0-10) 
PN006 … how much pain you have right now. Numeric (0-10) 
   
 (Pain interference) On a scale of 0 to 10, where 0 is “Does not interfere” and 10 is “Completely 
interferes”, select the one number that describes how, during the past 24 hours, pain has interfered with 
your … 
 
PN009 … general activity. Numeric (0-10) 




PN011 … walking ability. Numeric (0-10) 
PN012 … normal work (includes both work outside the home and housework). Numeric (0-10) 
PN013 … relations with other people. Numeric (0-10) 
PN014 … sleep. Numeric (0-10) 
PN015 … enjoyment of life. Numeric (0-10) 
CN Cognitive difficulties  
CN001 How would you rate your memory at the present time? Excellent/Very good/Good/ 
Fair/Poor 
CN002 Overall in the last 30 days, how much difficulty did you have with concentrating or remembering things? None/Mild/Moderate/ 
Severe/Extreme/cannot do 
CN003 Overall in the last 30 days, how much difficulty did you have in learning a new task (for example, 
learning how to get to a new place, learning a new game, learning a new recipe)? 
None/Mild/Moderate/ 
Severe/Extreme or cannot do 
PF Difficulties with ADLs (Katz Index of Independence in Activities of Daily Living)  
 We need to understand difficulties people may have with various activities because of a health or physical 
problem. Please tell me whether you have difficulty performing any of the following tasks on a regular 
basis. Exclude any difficulties that you expect to last less than three months. Because of health and 
memory problems, do you have any difficulty with … 
 
PF001 … walking across a room? Yes/No/Can’t do/Don’t want to 
PF002 (if yes) … Do you ever use equipment or devices when crossing a room? Yes/No 
PF004 (if yes) … Does anyone ever help you get across a room? Yes/No 
PF005 … dressing? Dressing includes taking clothes out, putting them on, buttoning up, and fastening a belt. Yes/No/Can’t do/Don’t want to 
PF006 (if yes) … Do you ever use equipment or devices when dressing? Yes/No 
PF008 (if yes) … Does anyone ever help you with dressing? Yes/No 
PF009 … bathing or showering? Yes/No/Can’t do/Don’t want to 
PF010 (if yes) … Do you ever use equipment or devices when bathing or showering? Yes/No 
PF012 (if yes) … Does anyone ever help you with bathing or showering? Yes/No 
PF013 
 
… eating, such as cutting up your food? (Definition: By eating, we mean eating food by oneself when it is 
ready.) 
Yes/No/Can’t do/Don’t want to 
PF014 (if yes) … Does anyone ever help you with eating? Yes/No 
PF015 … getting into or out of the place where you sleep? Yes/No/Can’t do/Don’t want to 
PF016 (if yes) … Do you ever use equipment or devices when getting into or out of the place where you sleep? Yes/No 
PF018 (if yes) … Does anyone ever help you with getting into or out of the place where you sleep? Yes/No 
PF019 … using the toilet, including getting up and down? Yes/No/Can’t do/Don’t want to 
PF020 (if yes) … Do you ever use equipment or devices when using the toilet? Yes/No 




Appendix Table 5.10 Bivariate associations between hypothesized confounders and exposure and outcome variables 
 Exposure categories (HIV continuum stage) Outcomes (CVD risk behaviors) 




Smoking Alcohol Sedentary 
behavior 
Potential confounder PR (90% CI) PR (90% CI) PR (90% CI) PR (90% CI) PR (90% CI) PR (90% CI) 
Demographics       
Male 0.80 (0.65, 0.99) 0.88 (0.62, 1.25) 1.03 (0.89, 1.18) 52.15 (27.93, 97.36) 3.54 (2.90, 4.33) 0.95 (0.89, 1.01) 
Age 0.94 (0.93, 0.95) 0.93 (0.91, 0.95) 0.95 (0.94, 0.95) 0.97 (0.96, 0.98) 1.00 (0.99, 1.00) 1.02 (1.02, 1.02) 
Education 1.43 (1.13, 1.83) 2.29 (1.59, 3.31) 1.41 (1.19, 1.67) 1.14 (0.93, 1.41) 0.61 (0.47, 0.79) 0.76 (0.70, 0.83) 
Employment 1.75 (1.36, 2.24) 1.29 (0.82, 2.02) 1.55 (1.30, 1.86) 1.40 (1.13, 1.72) 0.98 (0.77, 1.24) 0.65 (0.59, 0.72) 
Married 0.47 (0.38, 0.59) 0.57 (0.40, 0.81) 0.52 (0.45, 0.60) 0.98 (0.82, 1.16) 1.09 (0.92, 1.29) 0.86 (0.81, 0.91) 
Poorest 40% 1.31 (1.06, 1.61) 1.20 (0.85, 1.70) 1.23 (1.07, 1.42) 1.59 (1.34, 1.90) 2.28 (1.92, 2.72) 1.03 (0.97, 1.10) 
CVD history       
Hypertension 0.52 (0.42, 0.66) 0.72 (0.50, 1.03) 0.60 (0.52, 0.70) 0.36 (0.29, 0.44) 0.55 (0.45, 0.66) 1.25 (1.18, 1.33) 
Dyslipidemia/heart 
disease 0.63 (0.44, 0.90) 0.62 (0.33, 1.14) 0.90 (0.72, 1.12) 0.57 (0.41, 0.79) 0.64 (0.47, 0.88) 0.98 (0.90, 1.07) 
Diabetes 0.53 (0.31, 0.89) 0.72 (0.34, 1.55) 0.65 (0.47, 0.90) 0.27 (0.14, 0.51) 0.17 (0.08, 0.38) 1.25 (1.14, 1.38) 





Appendix Table 5.11 Predicted prevalence of CVD risk behaviors by HIV continuum stage overall, and stratified by sex 
 Tobacco smoking Hazardous alcohol use Sedentary behavior 
 Prevalence1 (95% CI) Prevalence (95% CI) Prevalence (95% CI) 
Overall (n=4,061)  
HIV continuum stage    
HIV− 9.3% (8.3%, 10.4%) 9.7% (8.7%, 10.8%) 43.1% (41.3%, 44.8%) 
HIV+ unaware 7.9% (5.2%, 10.7%) 10.2% (6.9%, 13.4%) 47.4% (40.9%, 53.8%) 
HIV+ aware untreated 10.6% (5.1%, 16.0%) 10.8% (4.6%, 16.9%) 39.7% (29.1%, 50.3%) 
HIV+ on treatment 8.8% (6.8%, 10.8%) 8.1% (6.1%, 10.2%) 38.8% (34.7%, 42.9%) 
    
Males (n=1,858)  
HIV continuum stage    
HIV− 19.9% (17.7%, 22.0%) 16.2% (14.3%, 18.2%) 42.0% (39.5%, 44.6%) 
HIV+ unaware 17.8% (12.2%, 23.4%) 17.6% (11.9%, 23.3%) 43.5% (33.3%, 53.8%) 
HIV+ aware untreated 22.2% (12.1%, 32.3%) 12.5% (3.4%, 21.6%) 39.1% (22.8%, 55.5%) 
HIV+ on treatment 19.0% (15.1%, 23.0%) 12.8% (9.2%, 16.3%) 39.4% (33.6%, 45.2%) 
    
Females (n=2,203)  
HIV continuum stage    
HIV− 0.3% (0.0%, 0.6%) 4.2% (3.2%, 5.1%) 43.9% (41.6%, 46.3%) 
HIV+ unaware 0.0% (0.0%, 0.0%) 4.0% (0.9%, 7.2%) 49.9% (41.5%, 58.2%) 
HIV+ aware untreated 0.0% (0.0%, 0.0%) 11.4% (1.0%, 21.8%) 40.5% (26.4%, 54.6%) 
HIV+ on treatment 0.5% (0.0%%, 1.3%) 4.7% (2.2%, 7.2%) 38.1% (32.4%, 43.8%) 
    
1 Prevalence was estimated using log-poisson regression with robust SEs, adjusted for adjusted for sex, age, education (at least 
primary), employed (full or part-time), married, wealth index (poorest 40% vs. richest 60%), hypertension, dyslipidemia, 




Appendix Table 5.12 Comparison of complete case sample and multiple imputation (MI) 
sample 






Variable n (%) n (%)  
Demographics    
Male 1,858 (46%) 2,122 (46%) 0 (0.0%) 
Age group   0 (0.0%) 
40-49 767 (19%) 827 (18%)  
50-59 1,177 (29%) 1,287 (28%)  
60-69 1,099 (27%) 1,213 (26%)  
70+ 1,018 (25%) 1,283 (28%)  
Completed primary education 826 (20%) 892 (19%) 14 (0.3%) 
Employed (full or part-time) 669 (16%) 731 (16%) 10 (0.2%) 
Married 2,142 (53%) 2,373 (52%) 3 (0.1%) 
Poorest 40%1 1,623 (40%) 1,889 (41%) 0 (0.0%) 
HIV-related    
HIV continuum stage   0 (0.0%) 
HIV– 3,038 (75%) 3,478 (76%)  
HIV+ unaware 275 (7%) 302 (7%)  
HIV+ aware untreated 93 (2%) 104 (2%)  
HIV+ on treatment 655 (16%) 726 (15%)  
Virally suppressed (among HIV+) 513 (54%) 568 (54%) 4 (0.4%) 
CVD risk behaviors    
Tobacco smoking2 371 (9%) 416 (9%) 3 (0.1%) 
Hazardous alcohol use3 386 (10%) 444 (10%) 2 (0.0%) 
Sedentary behavior4 1,731 (43%) 2,120 (47%) 0 (0.0%) 
CVD history    
Hypertension 1,725 (42%) 1,975 (43%) 2 (0.0%) 
Dyslipidemia or heart disease 513 (13%) 588 (13%) 22 (0.5%) 
Diabetes 270 (7%) 325 (7%) 1 (0.0%) 
Physiological symptoms    
Muscle weakness 2,660 (66%) 2,939 (64%) 214 (4.6%) 
Pain 343 (8%) 409 (9%) 86 (1.9%) 
Cognitive difficulties (memory/concentration/learning) 1,711 (42%) 2,005 (44%) 83 (1.8%) 
Physical dysfunction (difficulties with ADLs) 353 (9%) 562 (12%) 0 (0.0%) 
Psychological symptoms    
Depressive symptoms (CESD-8 score 5+ out of 8) 318 (8%) 395 (9%) 79 (1.7%) 
Low subjective well-being 1,163 (29%) 1,335 (29%) 143 (3.1%) 
1 Based on household wealth index. 
2 Self-reported current use of smoking tobacco (cigarettes, cigars or pipes). 
3 AUDIT-C score >4 for men, >3 for women out of 7 total points. 













Variable n (%) n (%)   
Demographics     
Male 1,858 (46%) 2,345 (46%) 0 (0.0%) 0.20 
Age group   0 (0.0%) <0.01 
40-49 767 (19%) 918 (18%)   
50-59 1,177 (29%) 1,410 (28%)   
60-69 1,099 (27%) 1,304 (26%)   
70+ 1,018 (25%) 1,427 (28%)   
Completed primary education 826 (20%) 1,020 (20%) 17 (0.3%) <0.01 
Employed (full or part-time) 669 (16%) 805 (16%) 14 (0.3%) <0.01 
Married 2,142 (53%) 2,575 (51%) 4 (0.1%) <0.01 
Poorest 40%1 1,623 (40%) 2,047 (41%) 0 (0.0%) <0.01 
HIV-related     
HIV continuum stage   449 (8.9%) <0.01 
HIV– 3,038 (75%) 3,478 (76%)   
HIV+ unaware 275 (7%) 302 (7%)   
HIV+ aware untreated 93 (2%) 104 (2%)   
HIV+ on treatment 655 (16%) 726 (15%)   
Virally suppressed (among HIV+) 513 (54%) 556 (53%) 4 (0.4%) 0.09 
CVD risk behaviors     
Tobacco smoking2 371 (9%) 460 (9%) 5 (0.1%) <0.01 
Hazardous alcohol use3 386 (10%) 479 (9%) 4 (0.1%) <0.01 
Sedentary behavior4 1,731 (43%) 2,372 (47%) 1 (0.0%) <0.01 
CVD history     
Hypertension 1,725 (42%) 2,118 (42%) 4 (0.1%) <0.01 
Dyslipidemia or heart disease 513 (13%) 641 (13%) 24 (0.5%) <0.01 
Diabetes 270 (7%) 352 (7%) 4 (0.1%) <0.01 
Physiological stress     
Muscle weakness 2,660 (66%) 3,145 (67%) 360 (7.1%) <0.01 
Pain 343 (8%) 439 (9%) 117 (2.3%) <0.01 
Cognitive difficulties 
(memory/concentration/learning) 
1,711 (42%) 2,223 (45%) 119 (1.8%) <0.01 
Physical dysfunction (difficulties with ADLs) 353 (9%) 634 (13%) 0 (0.0%) <0.01 
Psychological stress     
Depressive symptoms (CESD-8 score 5+ out of 8) 318 (8%) 442 (9%) 108 (2.1%) <0.01 
Low subjective well-being 1,163 (29%) 1,458 (30%) 179 (3.4%) <0.01 
This table shows comparisons of observed data between the complete case sample and full baseline cohort.  
 
 
 
